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Chapter 1 is a description of the basic fundamental concepts of porphyrins and 
BODIPYs, (including synthetic methodologies), a general mechanism of the processes of EGFR, 
and computational concepts that are elaborated upon in future chapters. 
Chapter 2 is a discussion solely on the porphyrins that were synthesized to be used as 
fluorophores for EGFR-targeted conjugates, both peptidic and non-peptidic.  The porphyrins 
were primarily synthesized via the Lindsey method as well as by O-alkylation of tetrahydroxy 
porphyrins.  Synthesis of PEG linkages are discussed as well through three methodologies. 
Chapter 3 is a presentation of the synthesis, characterization, cellular studies, and 
computational analysis of porphyrin-tyrphostin conjugates that will be used as potential in vivo 
imaging agents for CRC.  Two tyrphostin molecules that have affinity for EGFR, the BMNs and 
quinazolines, were synthesized and conjugated to PEG and or a porphyrin-PEG.   
Chapter 4 is a report of the development of porphyrin-peptide conjugates using two 
peptides, EGFR L1 (a six amino acid peptide) and EGFR L2 (a twelve amino acid peptide).  The 
peptides differ in charge, length, and hydrophobic character.  Porphyrin-peptide conjugates were 
synthesized via SPS or SNS methods using typical peptide coupling agents.  Cellular studies are 
also reported. 
Chapter 5 is a presentation of the synthesis and characterization of novel BODIPY-
peptidomimetic conjugates.  The peptidomimetic was designed computationally.  Two methods 
of conjugation are described: SNS with a tert-butyl ester protected peptidomimetic, and SPS. 
This work was done in collaboration with Professor S. Jois at University of Louisiana-Monroe. 
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CHAPTER 1. INTRODUCTION TO PORPHYRINS AND BODIPYS 
1.1 Fundamental Concepts of Naturally Occurring Porphyrins 
Porphyrins and their derivatives are typically highly fluorescent, aromatic molecules. The 
biocompatibility of the porphyrin macrocycle, its derivatives, and precursors (e.g. pyrroles), has 
been extensively studied and referenced through the literature." In consideration of basic animal 
and plant life, heme (Figure 1.1) and chlorophyll-a (Figure 1.2), respectively, are porphyrin 
derivatives.  Heme proteins are responsible for the transportation, storage, and activation of 
oxygen, the terminal electron acceptor for all aerobic respiration.2  Conversely, chlorophyll-a 
plays an important role in electron transfer and energy conversion in plants during 
photosynthesis, by capturing the light energy necessary for this process.2 It has also been 
illustrated that early life forms consist of porphyrin derivatives, potentially implicating their 
involvement in life on other planets, due to their high stability and versatility throughout 
evolutionary history.3  
   Heme porphyrins are biologically synthesized through a mechanism using delta-
aminolevulinic acid as a precursor and are transformed into protoporphyrin IX.4 It was first 
believed that these molecules were formed in vivo from glycine.  This fundamental amino acid 





















then reacted with a C4 compound to form the basic carbon skeleton of porphyrin. The 
intermediate becomes important in a decarboxylation process, which then undergoes a series of 
reactions to form porphyrin.5 Delta-aminolevulinic acid is then metabolized to porphobilinogen 
and porphyrin. Shemin and Russell first discovered the role of delta-aminolevulinic acid in 
1953.5 However, after further investigation, it was observed that eight enzymes are used to form 
the heme structure.  These enzymes are first enabled in the mitochondria.  After a series of 
reactions within the cytoplasm, the enzymes return to the mitochondria for heme formation. Any 
reaction regarding the biosynthesis of porphyrin, more specifically, heme, will take place in 
erythropoietic cells (red blood cells) or the liver parenchymal cells.  The cyclic tetrapyrrole 
intermediates formed through this biosynthetic pathway are porphyrinogens (that are then rapidly 
oxidized to produce porphyrin, or chlorin, in the case of chlorophylls).  Often, these structures 
contain some type of acetic or propionic acid on the carbon atoms of the pyrrolic carbons.4 
Depending on the porphyrin (uroporphyrin, coprotoporphyrin, or protoporphyrin) there will be a 
production of one of the three aforementioned naturally occurring porphyrins. Nonetheless, the 
exact synthesis of biologically relevant porphyrins would not have been realized without the 
work of Küster, who proposed the first structure of porphyrin in 1912.5-6!This structure was 
challenged and corrected by Hans Fisher, “the grandfather of porphyrin chemistry,” for which he 
was awarded the Nobel Prize.6 
1.2 Physico-chemical Properties of Porphyrins 
The porphyrin macrocycle possesses a 22-pi electron count with only 18-pi electrons 
involved in the aromatic structure. This organization allows for six varying delocalized pathways 
that obey Huckel’s Rule (4n+2) (Figure 1.3).1, 7 In fact, the aromaticity of the porphyrin gives 
several distinguishing characteristics in analysis of their physico-chemical properties.  The 
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proton NMRs of any porphyrin gives information about its aromaticity.  There is intense 
shielding of the internal N-H protons because of the anisotropic effect.  These N-H protons can 
be observed between -2 to 4 ppm.  Additionally, the external, or peripheral protons are most 
readily observed between 8 and 10 ppm.   
 
Porphyrins have characteristic UV-VIS spectra displaying a Soret band, an intense 
absorption at approximately 400 nm, depending on the substituents at the porphyrin periphery.  
The subsequent Q-bands are generally observed between 480-700 nm.1 Porphyrins are classified 
by their specific UV-VIS spectra.  The porphyrins described in this document are primarily etio-
type.7 The intensities of Q-bands are: IV>III>II>I, where IV corresponds to the Q-band at the 
shortest wavelength and Q-band I corresponds to the band at the longest wavelength.7  This type 
is characteristic of porphyrins in which six or more of the beta-positions are substituted with 
groups without pi electrons, such as alkyl groups or hydrogens.  
The 5,10,15,20-tetraphenylporphyrin, or TPP (1.4), is the parent molecule for these 
studies (1.4).  As observed in the figure, the structure is named according to the substituents at 
the meso, or methine bridges, of the porphyrin macrocycle. The addition of the phenyl rings to 
the porphyrin provides more conjugation due to partial overlap of pi-orbitals, despite the phenyl 
rings’ perpendicular position relative to the porphyrin ring, and therefore generally gives higher 
fluorescence intensity at longer emission wavelengths.  Fluorescence is a highly sensitive 
method of detection; the observed red shift in wavelengths, compared to the spectrum of the 
basic porphyrin macrocycle, implies that the molecule may be used in medicinal applications 
Figure 1.3. Delocalized Electron Pathways of the Porphyrin Macrocycle. 
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such as diagnoses of early cancers, for treatment in photodynamic therapy (PDT) and in vivo 
imaging, as to reduce background autofluorescence from blood and plasma, as discussed in 
Section 1.6.8 
 
1.3 Porphyrin Syntheses 
It is important to note three primary methods of synthesizing TPP and its derivatives, the 
porphyrin of choice for this study. These methods are those proposed by Rothemund and 
Menotti,9 Adler and Longo,10 with the most recent procedure devised by Lindsey.11  A variety of 
meso-substituted porphyrins can be prepared containing hydrophilic substituents such as –OH, -
OMe, as well as others, and extend conjugation of the porphyrin to further red shift absorbance 
and emission spectra. Three general methodologies known to prepare TPP and derivatives 
involve various conditions (harsh, high temperatures to mild, room temperatures) and give the 
target porphyrins in unequal yields. While there are also other methods to synthesize meso-
substituted porphyrins, these methods chiefly involve a mixed condensation mechanism to obtain 
the desired product(s). 
Figure 1.4. Structure of TPP and nomenclature system. 
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Rothemund and Menotti synthesized TPP varying ratios of pyrrole and benzaldehyde at 
high temperatures and the first description of their syntheses was noted in 1935.2, 12 The first 
synthesis used 0.44 M pyrrole and 0.58 M benzaldehyde in methanol at 90-95oC for 30 hours. A 
yield of 0.9% yield was achieved for TPP (Scheme 1.1), mainly due to formation of a chlorin 
contaminant in 10-20%. Chlorin, a dihydroporphyrin, can simply be transformed into porphyrin 
by an oxidation step. Later, in 1941, Rothemund and Menotti elaborated upon an improved 
synthesis of meso-TPP.9 
 
Scheme 1.1. Rothemund and Menotti Synthesis of TPP. 
This new attempt at the synthesis of TPP by Rothemund and Menotti consisted of combining 
benzaldehyde and pyrrole in a sealed tube at 150oC, using pyridine as the solvent. The highest 
yield obtained under these conditions was 11%.9, 12   
Adler and Longo10 used a milder set of conditions to synthesize TPP, as it had been noted 
that the concentration of reagents, temperature, acidity, and the availability of oxidant each 
played a significant role in this synthesis. The product was obtained by refluxing pyrrole and 















~ 0.9% 10% - 20%
MeOH, 90 - 95oC, 30 h
Oxidation
- 2e-, - 2 H+
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used to oxidize the intermediate porphyrinogen macrocycle. The yield for the Adler-Longo 
method was 20% ± 3% for TPP.10 This method gives higher yield of TPP, but does not allow the 
preparation of TPP derivatives containing sensitive groups on the meso-phenyl substituents. 
Therefore, the most recent method for synthesis of TPP is the Lindsey method (Scheme 
1.3).13 This method employs a more versatile approach to obtain derivatives, containing sensitive 
substituents, of interest.  Lindsey and co-workers realized that six different products, of the 
forms A4, A3B, cis-A2B2, trans-A2B2, AB3, and B4 (Scheme 1.3) could be synthesized by 
dissolving two different benzaldehydes and pyrrole in a dilute solution of dichloromethane (~10-2 
M). A Lewis acid catalyst, such as BF3.Et2O or, an acid, TFA, is added to the reaction mixture 
(~10-3 M).  The Lindsey product is a colorless porphyrinogen that must be oxidized to porphyrin 
with p-chloranil or DDQ.11 This is the most effective method to synthesize TPP, with a yield of 
up to 55% - a dramatic increase from previous approaches.  With this procedure, benzaldehydes 
functionalized with, A-benzaldehydes were of the following names: methyl-4-formylbenzoate, 
3,4,5-trimethoxybenzaldehyde, and 3,5-dimethoxybenzaldehyde.  The B-benzaldehyde was 
simply benzaldehyde.  Syntheses were optimized by varying the stoichiometry of the A- and B- 













R = H, OCH3, or OH
Scheme 1.2.  Adler and Longo Synthesis of TPP. 
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chromatography.  This method allowed for increased hydrophilic substituents on the phenyl rings 
of the porphyrin, which must be accounted for in regard to the potential of our molecules to be 
biologically relevant for in vivo imaging and as therapeutic agents.   
    
 
1.4 Physico-chemical Properties of BODIPY 
BODIPYs, or 4,4-Difluoro-4-bora-3a,4a-diaza-s-indacenes (Scheme 1.4), have been 
illustrated to be influential to scientists due to their versatility. These molecules were first 
synthesized by Treibs & Kreuzer in 1968, however, BODIPYs did not gain widespread 





























































2. Oxidation (DDQ or p-chloranil), 25oC
a colorless porphyrinogen
Scheme 1.3.  Lindsey Synthesis of TPP. 
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Position 8 is termed the “meso-position,” while positions 1, 2, 6, and 7 are termed the 
“beta-positions.”  The “alpha- positions” are at numbers 3 and 5. Coined less formally as 
“porphyrin’s little sister,”15a BODIPYs have numerous attractive characteristics, and as a 
consequence, interest in this field has increased exponentially over the past several years.  For 
example, the number of journal articles published in 2006 was nearly double of the decade 
before.15a  This illustrates that due to the BODIPY’s intricacies, a revolutionary method of 
developing new materials and fluorescent tagging agents can be constantly improved upon.  The 
primary aspects of BODIPYs that secure their attractiveness as fluorescent agents are the 
following: they are stable in many environments (acidic, basic, various temperatures), they have 
high fluorescence quantum yields (almost 1.0 in most solvents), they possess high molar 
extinction coefficients, and have inconsequential triplet state formation (a quality of important 
consideration in discussion of their fluorescence capabilities).15-16 BODIPYs are also being used 
in various medicinal and materials applications.17 
1.5 BODIPY Syntheses 
 Treibs and Kreuzer synthesized the first BODIPY by first constructing the 
dipyrromethene fragment followed by complexation with boron trifluoro diethyl etherate.14 This 
may be achieved by a condensation reaction, which is very similar to the synthesis of porphyrin 




















(Scheme 1.5). An !-substituted pyrrole and an electrophilic carbonyl compound are combined to 
form a dipyrromethane.  This is done in acidic conditions using TFA or a Lewis acid, in a solvent 
most suitable for solubility of the pyrrole and carbonyl compound. This reaction proceeds at 
room temperature and produces the dipyrromethane backbone of BODIPY.  The next step is to 
oxidize the dipyrromethane unit by using DDQ or p-chloranil. The BODIPY used for these 
studies is 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-pentanoic acid, a 
compound which is commercially available. 
  
 Subsequent complexation of the pyrrolic nitrogens to boron using boron trifluoro diethyl 
etherate in base completes the synthesis of BODIPY. The overall yield for synthesis of a 
symmetric BODIPY was approximately 22%, although the Vicente group can produce BODIPYs 
in 55-90% yields.18  These yields vary depending upon the nature of the substituents on the 

































Scheme 1.5. Synthesis of BODIPY. 
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1.6 Medicinal Applications of Porphyrins and Related Derivatives 
Porphyrins have proven to be efficacious in medical screening and treatment of cancer.  
Most notable may be their use in PDT, a cancer treatment which consists of a photosensitizer 
(porphyrin derivative) that is injected into the body, localizes in the tumor cells, and after 
irradiation with light, becomes highly cytotoxic to the tumor cells.19  
    
 Two porphyrin-based pharmaceuticals, Photofrin® (Figure 1.6) and VisudyneTM (Figure 
1.7) are FDA approved and have been used for several years for the treatment of cancer.19-20  
Figure 1.6. Structure of Photofrin. ® 







































































1.7 In vivo Imaging 
Cancer imaging is becoming a primary consideration as preventative medicine for CRC. 
Our design of imaging agents is for them to be used in confocal laser endomicroscopy (CLE), a 
staunch improvement upon colonoscopy and other methods in screening for CRC. PDT and 
previous research in the Vicente group has illustrated the efficacy of porphyrins as potential in 
vivo imaging agents and PDT agents with low dark cytotoxicity.17e, 20a, 21 
The technique of in vivo imaging employs a type of visual apparatus to obtain a view of 
the colon.  In years past, the medicine has developed several approaches to enhance the view of 
the colon.  One of the more notable methods is that of flexible sigmoidoscopy. The endoscope is 
then advanced under direct vision and moved around the various bends in the lower bowel. The 
exam usually is very short and more importantly, the patient does not have to be sedated. 
Another advantage of flexible sigmoidoscopy is that polyps and tumors can be detected at early 
stages.22  Additional methods of in vivo imaging are standard colonoscopy, chromoendoscopy, 
both of which have proven somewhat effective in detection of colorectal cancers.22 
Scheme 1.6. Mechanism of CLE.26 
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CLE is our means of arriving to successful in vivo imaging of CRC.  CLE (Scheme 1.4) 
provides better spatial resolution than colonoscopy. Using laser light, which is incorporated into 
the tip of an endoscope, a laser light is emitted onto the mucosal surface of colorectal tissues and 
into deeper portions of the mucosal layer. CLE has been illustrated to be effective clinically as 
well.  In a study published by Kiesslich and colleagues, it was found that CLE could determine a 
change in a particular polyp with 97.4% sensitivity, 99.4% specificity, and 99.2% accuracy.23 
Conversely, other imaging agents, such as cresyl violet and fluorescein, stain tumor cells non-
selectively, with normal and cancerous cells being colored.20d, 24 Besides this fact, these are 
ineffective due to their poor water solubility, lower quantum yields, and emit at lower 
wavelengths that are not close to the NIR-range. This research, then, is advantageous in that 
fluorescent porphyrin molecules can be synthesized and used to selectively label CRC tumor 
foci. 
1.8 Epidermal Growth Factor Receptor (EGFR) 
EGFR (Figure 1.8), a single polypeptide chain consisting of 1186 amino acid residues, 
has been found to be an integral piece in attempting to find an effective treatment for CRC and 
other cancers.  EGFR is found in 98% of colon cancers and are abundantly over-expressed on 
small cancers.25  
Activated first by binding of growth factor ligands (i.e. EGF), in eukaryotic cells, EGFR 
undergoes dimerization, then stimulates its inherent protein-tyrosine kinase activity, thereby 
catalyzing the phosphorylation of tyrosine residues.25a, 26 EGFR overexpression is a mutation that 
could cause uncontrolled cell proliferation and is therefore associated with cancer.26 The 
discovery of EGFR’s importance to CRC and other cancers has led to the discovery of peptidic 
ligands, with high specificity for the receptor. Erbstatin, a tyrphostin derivative known to inhibit 
! 13 
the EGFR tyrosine kinase domain, and the 4-anilinoquinones, most notably called the 
quinazolines inhibit the receptor via a similar mechanism.25, 27 EGFR and its family of receptors 
(HER-2/ERBB2, ERBB3, ERBB4) have been recognized as critical proteins involved in 
carcinogenesis.! 
 
1.9 Molecular Dynamics and Ab initio Computational Calculations 
Computational chemistry has proven to be a propitious method in proceeding with 
synthesis of molecules believed to be medicinally beneficial.  Molecular dynamics (MD) and 
quantum mechanics (QM) ab initio methods were used to understand energy conformations, 
relative water solubility, and relative electronic stability for our selected molecules. These 
methods include: AutoDock/AutoDock Vina (MD), Restricted Hartree-Fock (RHF; QM) and 
Moller-Plessett (MP; QM).  
The molecular dynamics computations were conducted on larger porphyrin conjugates, 
all of the tyrphostins and peptides selected for this dissertation research.  The software, 
Figure 1.8. EGFR Heterodimer.27 
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AutoDock and its counterpart, AutoDock Vina (noted herein as “Vina”), were used to 
concentrate on one ligand (the peptide or tyrphostin), one enzyme (EGFR) binding.28  The ligand 
with the lowest binding energy may illustrate that the ligand is the most stable for the EGFR 
active site. The data consists of a list of all molecules ranked according to their binding energies.  
These results were gathered using three tools: a docking algorithm, the enzymatic target, and a 
ligand library consisting of the porphyrin conjugates of interest. 
AutoDock and Vina are the docking algorithms by which the binding energies of the 
ligands were determined in their possible orientations. The concept behind the method is that of a 
Lamarkian genetic algorithm; the ligand models as a chromosome, which in this case consists of 
its own genetic characteristics (location, orientation, and conformation).28-29 The enzyme remains 
stationary, while the ligand “walks” around the enzyme. This “walk” takes place in a grid box 
(1.9), the search area centered on a region of interest on the enzyme. As the ligand makes its trek, 
the ligand is actually producing an offspring, each being an attempt to find the most stable 














Figure 1.10. Hess’ Law for Protein-Ligand Docking. 
The above diagram accounts for Hess’ Law (1.10) by the following equation for the binding free 
energy in solution: 
"Gbinding, solution = "Gbinding, vacuo + "Gsolvation (EI) - "Gsolvation (E+I) 
Equation 1. Determining "Gbinding, Hess’ Law 
The rate of this reaction is measured using:  
Ki = e("Gbind/RT), where R=8.314 J/mol K and T=temperature in Kelvin. 
Equation 2. Reaction Rate Equation 
As previously stated, our enzymatic target structure is that of pure EGFR. This structure 
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successful in determining potential drug interactions within an active site of an enzyme, this 
must only be used as an introduction to the design of novel pharmaceuticals. Many obstacles 
arise in computational work due to the complexity of the potential interactions between the 
ligand and the enzyme.  Since binding energies are ranked according to the scoring function, 
false positives may occur.  AutoDock 4 uses the AMBER force field, while Vina uses its own 
parameterized force field.  Due to this fact, there may be flaws within the force field itself.  Even 
improper consideration of the ligand or enzyme’s orientation, location, and conformation can 
impact the overall calculation.  If, however, one is able to obtain a lead compound within a 
nanomolar concentration, this proves the efficacy of computational work. Although AutoDock 
may be used more frequently among those in academia,32 every study conducted on simulation 
software does not prove better than others.  Therefore, these studies must be used to enrich 
ligands for novel porphyrin conjugate design.33 Using the crystal structure of EGFR, AutoDock 
and Vina, which were both developed at the Scripps Research Institute and are both now highly 
utilized tools in drug discovery, were used to observe potential interactions. 
Conversely, the ab initio methods begin with the fundamental “basis set.” The basis set is a 
representation of the atomic orbital, centered on a particular nucleus.29 It has been observed that 
a combination of Slater-type orbitals and Gaussian-type orbitals give better energy 
approximations.29 This is how the minimal basis set is constructed; it takes into account the 
number of functions required to accommodate all the filled orbitals in each atom of the molecule.  
The absolute minimum basis set, STO-3G, is important, as it provides an initial visualization of 
the molecular geometry for a particular molecule.34 In addition to these considerations, it must be 
realized that these minimum basis sets do not account for valence electron activity, which can 
highly determine the energetic state of the molecule.  Therefore, using a split valence double zeta 
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basis set, such as 3-21G, accounts for three Gaussians (core orbitals), two contracted valence 
electrons and one diffuse valence electron orbital.  If, however, electrons could potentially be 
attracted to other nuclei in a particular molecule, polarization functions must be introduced.34 
These types of basis sets are notated by addition of an asterisk (*).  The anionic nature of a 
molecule is considered using diffuse functions toward a basis set.  This is accounted for by 
addition of a plus (+).  This function allows basis sets to deal with any significant electron 
density that is located away from the atomic nucleus.34 
One of the main methods of ab initio calculation used was Restricted Hartree-Fock 
(RHF).  With this method, we must consider the Variational Principle, which states that the 
energy calculated from an approximation to the true wavefunction will always be greater than the 
true energy, where a lower energy value obtained implies a more accurate wavefunction.29 
Electrons are able to ‘see’ each other and allowed to feel electronic effects, such as electron-
electron repulsion.  The main disadvantage of Hartree-Fock theory is that these electrons are 
assumed to move within the average potential of the other electrons, when in actuality, these 
electrons tend to avoid each other more than theory suggests, thereby giving a lower energy, 
when this may not be the case.35 Essentially, Hartree-Fock is a deliberately approximate theory.35 
Conversely, Moller and Plesset attempted to include electron correlation in their method, 
which must be considered.  The “many-body perturbation theory” can occasionally give energies 
that are lower than the actual energy.  This level of theory is computationally intensive and 
usually requires that geometries are optimized before using it.  In quantum mechanics 
computational analysis, this theory incorporates the issue of electron correlation.35 
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The molecular dynamics and ab initio methods used for these studies gave a thorough 
understanding of these molecules’ electron interactions and properties.  This will assist in the 
future design and synthesis of porphyrin peptidic and non-peptidic conjugates for improvement 
of in vivo imaging techniques of CRC.   
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CHAPTER 2. SYNTHESIS OF MESO-SUBSTITUTED TETRAPHENYLPORPHYRINS 
AS FLUOROPHORES IN EGFR TARGETED CONJUGATES 
2.1 Syntheses of meso-Substituted Porphyrins 
 Since the improvement on the synthesis of TPP by Adler and Longo,1 then by Lindsey,2 it 
is evident that the development of TPP has been heavily studied over the past fifty years. In order 
to synthesize derivatives of TPP, several methods have been used in addition to those described 
by Adler, Longo and Lindsey, such as the [2+2] and [3+1] methodologies.3 The MacDonald 
[2+2] synthesis requires the condensation of two dipyrromethanes or dipyrromethenes, while the 
[3+1] intermediate methodology consists of the reaction between a tripyrrane and a 
monopyrrole.3 The enrichment of these methods allows for the achievement of higher yields for 
asymmetrical porphyrin molecules. In this work, we will concentrate on the methods of 
asymmetrical porphyrin synthesis, specifically beginning with the Lindsey method.2 
2.2 Synthesis of Mono-amino and Mono-carboxyl Tetraphenylporphyrins via the Lindsey 
Method 
The synthesis of 5-(4-aminophenyl)-10,15,20-triphenylporphyrin (2-3) was similar to that 
reported by Luguya et al (Scheme 2.1).4 However, the overall yield was lower (15%), maybe due 
to differences introduced in the protocol. TPP (2-1) was synthesized using Lindsey’s conditions 
using pyrrole, benzaldehyde, and methyl-4-formylbenzoate with boron trifluorodiethyl etherate 
and subsequent oxidation using DDQ. To continue the synthesis, TPP was nitrated using NaNO2 
in acidic conditions, promoting formation of the nitrate electrophile and thus electrophilic 
aromatic substitution. The nitro group was then reduced using SnCl2 in HCl to afford mono-
amino porphyrin 2-3, which was then subjected to a nucleophilic reaction with diglycolic 
anhydride to give the carboxylic acid terminated porphyrin 2-4.  The carboxylic acid terminus 
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would have allowed for conjugation to peptides and a PEG linker. Unfortunately, the many 








































































Scheme 2.2.  
Scheme 2.1.  
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Although the yield from adding the diglycolic anhydride was very high (98%), there was 
not enough material to continue further. Therefore, an alternative synthesis was conducted, 
beginning with porphyrin 2-5, which was prepared using a mixed aldehyde condensation with 
pyrrole and benzaldehyde, as shown in Scheme 2.1. Using porphyrin 2-5 as the starting material 
in DIEA, a coupling reaction followed, using HOBt, TBTU, and glycine tert-butyl ester.  In this 
manner, one amide bond was formed in very high yield (Scheme 2.2). The addition of the 
glycine also provides space between large porphyrin, PEG linker or biomolecule for conjugation. 
This also increases yields of conjugations of porphyrin to the biomolecules of choice for these 
studies. To produce the carboxylic acid terminated porphyrin 2-7, the Boc-protected porphyrin 
(2-6) was deprotected with TFA in DCM. The alternative method shown in Scheme 2.2 gives 
similar terminal carboxyl functionality for coupling of the porphyrin to amine groups on a linker 
or peptide. However, the overall difference in structure is important to note between compounds 
2-4 and 2-7; compound 2-4 contains a total of seven atoms in a chain with five hydrogen 
bonding atoms potentially effecting future conjugation, while compound 2-7 contains a total of 
five atoms in a chain with four hydrogen bonding atoms. It is also important to illustrate the 
presence of two additional carbon atoms in the short 2-4 linkage, while 2-7 only contains one 
additional carbon atom.   
While the porphyrins used consisted of only one substituent at the para-position of one of 
the phenyl rings of the TPP derivatives, another, more hydrophilic porphyrin was synthesized 
using the method of mono-functionalization, more specifically, through O-alkylation.  This 
method consisted of using commercially available 5,10,15,20-tetrakis(4-hydroxyphenyl)-
porphyrin (2-8), as shown in Scheme 2.3. Previously in our group,5 this reaction was conducted 
in anhydrous DMSO using a slightly different protocol than the one illustrated in Scheme 2.3.  
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To activate the hydroxyl groups of 2-8, K2CO3 was used first, but after initial lower yields (2%-
5%) for the O-alkylation reaction, Cs2CO3 was used.  The reaction was conducted in DMF and it 
was evident that the use of Cs2CO3 greatly improved the yield of the reaction.  Cs2CO3 has been 
demonstrated to be more soluble in organic solvents and is at least ten times more soluble in 
aprotic organic solvents, such as DMSO or DMF.6 Cs2CO3 is also more basic in comparison to 
K2CO3.7 The difference in this O-alkylation reaction, in comparison to the published procedure, 
is mostly in the time of the reaction;5 instead of conducting the reaction at 60oC, the reaction was 
done at 70oC for 4 hours and the activation of hydroxyl groups took place for approximately 30 
minutes. The yield for the new reaction conditions ranged from 20%-39%. 
 
2.3 Synthesis of Polymethoxy Tetraphenylporphyrins via Lindsey Conditions 
In Chapter 1, Section 1.8, two tyrphostin-based molecules were mentioned as having 
affinity for EGFR.  One class of molecule, the benzylidenemalononitriles (BMN), contains 


































1. Cs2CO3, 0.5 h
2. tert-butyl 2-bromoacetate
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several hydroxyl substituents (Figure 2.2).  Through 3D-QSAR studies, it was evidenced that 
these hydroxyl moieties are important for affinity of these molecules for EGFR.8 In terms of 
binding modes, it was illustrated that in the active site of EGFR 1 and EGFR 2, having the 
polyhydroxy groups on the phenyl ring favors binding.8b This is because these compounds 
resemble tyrosine and erbstatin-type analogs, which were found to have affinity for this 
receptor.8a In fact, based on computational studies, the phenolic ring is a requirement of the 
BMN tyrphostin to have any activity toward the receptor.8c With these facts, it was hypothesized 
that by incorporating more hydrophilic substituents, such as hydroxyl groups, into our design of 
novel in vivo imaging agents, we could mimic the structure of the tyrphostin BMNs and also 
increase water solubility of our porphyrin conjugates, which could also inhibit aggregation of the 
porphyrin conjugate in aqueous media.  
 
 It is evident from Figure 2.2 that one tyrphostin, AG18, has two hydroxyl groups on the 
phenyl ring, while the other, AG82, has three.  They also have different IC
50 
values, with AG82 
having the highest affinity for EGFR in this particular study.8a This would imply that the 
potential of synthesizing porphyrins with three hydroxyl groups on the phenyls of TPP-based 
porphyrins might show more promising results in comparison with only two hydroxyl groups on 
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Figure 2.2. Structures of Tyrphostins Containing BMN 
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Several attempts at synthesizing the trimethoxyporphyrin using a mixed condensation 
with pyrrole, methyl-4-formylbenzoate, and 3,4,5-trimethoxybenzaldehyde were done (Table 
2.1, Scheme 2.4). To optimize the condensation reaction, several ratios of pyrrole, methyl-4-
formylbenzoate, and 3,4,5-trimethoxybenzaldehyde were used to achieve the highest yields for 
porphyrin 2-11 using Lindsey conditions.2 The reaction began with the starting materials in a 
4:1.5:3 (pyrrole: 3,4,5-trimethoxybenzaldehyde: methyl-4-formylbenzoate) ratio.  Methoxy-
protected hydroxyl groups were used for several reasons. Primarily, using protected hydroxyl 
groups is easier to purify by column chromatography, as more polar compounds tend to be 
retained on the silica gel.  Additionally, it has been reported that using a higher ratio of 
aldehydes with the Lindsey method of porphyrin synthesis does not generally give good yields of 
the target porphyrins.9 Therefore, in using methoxy groups, higher yields were expected for this 
synthesis.  Other methods for achieving more polar porphyrin compounds tend to use higher 
temperatures and propionic acid, yet still achieving low yields.9  As shown in Table 2.1, the best 
ratio of aldehydes and pyrrole was that of Method C. It seems that the ratio of the electron 
withdrawing methyl ester benzaldehyde (methyl-4-formylbenzoate) may have some effect on the 
overall yield in conjunction with the more electron donating trimethoxybenzaldehyde. A higher 
ratio of methyl ester benzaldehyde may have simply been less reactive when compared to the 
other benzaldehyde. The unequal ratios gave unequal yields of all possible porphyrins, however, 
the ratios of Method C gave the highest yield for the target porphyrin 2-11 containing only one 
methyl ester group. 
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Table 2.1. Ratios of Starting Materials for the Synthesis of 5,10,15-(3,4,5-
















A 3 4 1.5 <1% 
B 6 4 1.5 5% 
C 6 4 0.7 9% 
D 9 4 1.5 <1% 
 
2.4 Synthesis of Propargyl Porphyrins for Use in These Applications 
 The use of the propargyl functionality has been used to facilitate the “click chemistry,” or 
Huisgen 1,3-dipolar cycloaddition,10 to create a triazole linkage between porphyrins (and their 
respective carbohydrate conjugates for improvements in PDT) and other types of molecules.11 
The linkage allows for azide-terminated molecules (such as PEGs) to be easily conjugated 
without any side products and minimal purification (e.g. crystallization or distillation).10  The 


























Scheme 2.4.  
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improvement of these molecules to be used in biological applications, such as PDT and in vivo 
imaging. This section will discuss the synthesis of these propargyl porphyrins. 
2.4.1 Synthesis of 5-(4-propargylphenyl)-10,15,20-tri(4-hydroxyphenyl)porphyrin 
Porphyrin was synthesized for future use in “click chemistry” reactions with azide-
terminated PEGs. These PEGs would be used to conjugate epidermal growth factor peptide (EGF 
peptide) as a comparison to smaller porphyrin-peptide conjugates that were synthesized and will 
be discussed in Chapter 4.  It was also thought that in synthesizing this porphyrin, there could 
be additional synthetic usage by converting the propargyl group for a malononitrile substituent, 
which is in the tyrphostin series of porphyrin conjugates (Chapter 3).  This procedure was 
modified from one noted previously in our group, by using Cs2CO3 as the base in DMF or THF, 
then alkylation with propargyl bromide or propargyl chloride, which stirred for 4 hr under 
nitrogen (Scheme 2.5).  The initial reaction with propargyl chloride in DMF was completely 
unsuccessful, most likely due to the lower reactivity of chloride compared to bromide, and that 
DMF was used, which tends to inhibit SN2 reactions.  However, when the reaction was 


























Scheme 2.5. Synthesis of a Propargyl-Terminated Porphyrin via Mono-O-
Alkylation of Tetra-Hydroxyl Porphyrin. 
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with the production of other alkylated products, which were separated on column 
chromatography using CHCl3/ethyl Acetate (8:2) in 35% yield.  
2.5 Synthesis of PEGs and Pegylated Porphyrins 
This research uses strategies to improve the delivery of fluorescent porphyrin or BODIPY 
molecules to CRC cells as well as advance small tumor detection using confocal laser 
microscopy.  The approach involves conjugation of two types of biomolecules, a small peptide 
ligand or tyrphostin derivative, to the porphyrin via a PEG linker (3-, 4-, or 5-PEG). This is an 
important component of the fluorescent conjugates. PEGs are soluble synthetic polymers that 
have properties suitable for medicinal applications. Furthermore, it has been shown that PEGs 
increase water-solubility, decrease aggregation, and enhance cellular uptake of the conjugates.12 
Journals such as Biomacromolecules have recently published articles to describe the importance 
of the PEG to biologically active molecules.13 The PEG is an essential piece of our porphyrin 
conjugate, which has been analyzed both biologically and computationally in our group. 
Previous computational studies suggested that a linker consisting of at least 15 atoms would 
favor an extended conformation of the conjugates, which may favor receptor binding.14 
2.5.1 Structures and Synthesis of PEG Linkages 
Due to the improvements in the pharmaceutical industry regarding drug delivery directly 
to a specific organelle or type of tumor cell, there has also been development of PEG linkers to 
attach to these drugs.  Porphyrins tend to aggregate in aqueous media because of their primarily 
hydrophobic backbone.15 In order to alleviate some of these issues, three types of linkers were 
used.  The first two, tert-butyl 12-amino-4,7,10-trioxadodecanoate (NH2-3PEG-tBu) and Fmoc- 
1-amino-4,7,10-trioxa-tridecanamine succinimic acid (Fmoc-3PEG), were conjugated to 





The first coupling of PEG was conducted to conjugate porphyrin 2-7 to amine-terminated 
PEG linkers. A 15-atom PEG linker, or NH2-3PEG-tBu, is available commercially from Sigma-
Aldrich. It contains a free amino terminus that allows coupling to the carboxylic acid group of 
porphyrin 2-7 using the aforementioned peptide-coupling agents and conditions: HOBt, TBTU, 
and DIEA, in DMF (Scheme 2.6). Porphyrin-PEG 2-13 was then deprotected with TFA (2-14), 
washed with cold anhydrous ether several times, then carried on to conjugations to the small 
biomolecules used in this study that have an affinity for EGFR (peptides, BMNs, quinazolines as 
described in Chapters 3 and 4).  The compound, 2-13, has not been reported in previous 
literature, and after coupling the PEG to the porphyrin, a yield of 60% was achieved after 




















Figure 2.3. Structures of Commercially Available PEGs Used in This Study - (A) 
Tert-butyl 12-amino-4,7,10-trioxadodecanoate (NH2-3PEG-tBu) and  
(B) Fmoc- 1-amino-4,7,10-trioxa-tridecanamine succinimic acid (Fmoc-3PEG). 
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 A second coupling of the PEG was conducted with porphyrin 2-10. Similar coupling 
procedure was used with DIEA, HOBt, and TBTU. However, the high polarity of this compound 
required purification by RP-HPLC, yet was obtained in moderate yield (18%). Pegylated 
porphyrin 2-15 can also be used in future conjugations to biomolecules such as peptides, 










































2. NH2-3PEG-tBu (Figure 2.3 (A))

























2. NH2-3PEG-tBu (Figure 2.3 (A))




2.5.2 Synthesis of 5-PEG 
Ab initio calculations, using RHF//6-31G* computational method on Gaussian 03, and 
molecular dynamics calculations, using the Gasteiger-Huckel model designed within the Tripos 
Force Field in SYBYL 7.016 of a porphyrin conjugate suggest that a 5-PEG linker would favor a 
more open conformation of the conjugate.16 This preliminary computational study was conducted 
solely to assess the effect the PEG may have on the entire conjugate. Several methods were 
followed to synthesize the 5-PEG.                
The 5-PEG synthesis was attempted using various methods to obtain optimum synthesis 
conditions, as described in Schemes 2.6, 2.7, and 2.8.  The first step, as reported by 
Thumshirn,17 protects one end of hexaethylene glycol 2-16 using tert-butyl diazoacetate, 
reaching optimum reaction time of 15 minutes, which was monitored by TLC.  A shorter 
reaction time than was previously reported, minimized the formation of di-tert-butyl ester side 
product, which decreases the yield of the target product, as seen by TLC.  The second step of this 
synthesis was to produce the tosylate of the unprotected alcohol using TsCl in Et3N (Scheme 
2.7).  In comparison with previous attempts to protect the free alcohol using the mesylate,14 it 
was found that the tosylate is more stable and readily detected by UV light, which would assist in 
determining reaction completion via TLC.18 NaN3 was then used to displace the tosylate 
functionality, followed by the reduction of the azide to the amino group. The reduction of azide 
used 10% Pd/C catalyst under hydrogen.  ESI-MS and TLC were conducted at each step without 
purification.  The crude product was highly impure and was difficult to purify due to many polar 
and non-polar products evident on the TLC plate.  
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In an attempt to decrease the number of side products, another attempt to synthesize the 
5-PEG was conducted, beginning with TsCl.  Reaction completion of the first step occurred 
within 20 minutes.  Evidence of the di-substituted tosylate, the mono-substituted tosylate, and the 
starting material 2-16 were present by TLC and by MS analysis of the crude oil.  NaN3 was 
added to the reaction flask. The reaction mixture was heated under reflux for 2.5 hours as 
reported.14, 17 Reduction was, again, conducted using the Pd/C catalyst under hydrogen 
atmosphere. TLC indicated several compounds were present (Scheme 2.9). New compounds that 
were not obtained in Scheme 2.8 are circled.  
 
Another strategy introduced iodination of the alcohol, which should have made for a 
better leaving group (Scheme 2.10).  New compounds that were not obtained in Scheme 2.8 or 
Scheme 2.9 are circled. Tert-butyl diazoacetate was first added to 2-16, thereby adding a tert-






































DCM, 0oC-RT, 20 minDCM, RT, 35 min
Scheme 2.8. Method 1 - Synthesis of 5-PEG. 
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and I2, (respectively in that order) to replace the primary alcohol with iodide. Substitution of the 
iodide with azide and subsequent reduction with Pd/C catalyst remained the same.  TLC was 
used to observe product formation and relative purity.  While only two spots were visible by 
TLC, purification was difficult, as observed by 1H NMR after purification by flash 
chromatography as well as HPLC. The triphenylphosphine reagent is highly non-polar and did 
not separate from the other products. This method was abandoned, due to these issues.19  ! 
 
 It seems that the best method for the synthesis of the 5-PEG is to follow Scheme 2.8, as 
10% yield of the crude product was obtained.  According to Scheme 2.9, product was also 
obtained, but in a lower amount in comparison to that obtained from Scheme 2.8. 
2.6 Conclusions 
 This chapter is a presentation of the synthesis of porphyrins and their pegylated products.  
The porphyrin mostly used for the conjugation of biomolecules as described in Chapters 3 and 
4 are the TPP derivatives, 2-7 and 2-14.  These porphyrins were conjugated to the peptidic 
conjugates, which will be discussed in chapter 3.  Additionally, the types of PEGs used in this 
project were discussed.  There were essentially three types of PEGs used, the Fmoc-3PEG, NH2-
3PEG-tBu, and 5-PEG.  As noted previously, the PEG is very important to the overall stability 
and water-solubility of the conjugate within aqueous media.   
 











DCM, RT, 35 min
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Synthesis of 5-(4-aminophenyl)-10,15,20-triphenylporphyrin (2-3): To a solution of 2-1 
(0.100 g, 0.163 mmol), which was prepared by mixed condensation of distilled pyrrole and 
benzaldehyde, in TFA (10 mL), NaNO2 (0.020 mg, 0.29 mg) was added.  After 3 minutes stirring 
at room temperature, the reaction mixture was poured into water (100 mL) and extracted with 
DCM (6x25 mL).  The organic layer was washed with saturated aqueous Na2CO3 and water, 
dried with anhydrous MgSO4, filtered, and concentrated. The residue was purified on a small 
plug of silica gel, eluting with dichloromethane.  Solvent was evaporated and residue recovered. 
The residue was dissolved in concentrated HCl (10 mL) and while stirring, SnCl2 (0.220 g, 0.975 
mmol) was carefully added.  This mixture was heated to 65oC for 1 h under nitrogen before 
being poured into cold water (100 mL).  The aqueous solution was neutralized with ammonium 
hydroxide until pH 8.  The aqueous solution was extracted with dichloromethane until colorless.  
The organic layer was dried with anhydrous MgSO4, filtered, and concentrated under vacuum.  
Residue was purified on silica gel column using DCM/hexanes (1:1) for elution.  The final 
residue was recrystallized from DCM and methanol yielding 15% of 5-(4-Aminophenyl)-
10,15,20-triphenylporphyrin. ESI-MS 630.25 [M+H]+, calculated for For C44H31N5 629.75. 1H 
NMR, 13C NMR, and absorbance spectra were identical to that presented in literature.4 
Synthesis of Porphyrin 2-4: To a solution of 2-3 (0.200 g, 0.317 mmol) in 1 mL DMF, 
diglycolic anhydride (0.055 g, 0.476 mmol) was added.  Reaction mixture was stirred overnight 
at room temperature under nitrogen atmosphere.  After reaction completion, the mixture was 
diluted with 10 mL chloroform, followed by hexanes, until precipitation occurred.  The 
precipitate was filtered and washed with water to remove residual anhydride.  Precipitate was 
dried under vacuum, yielding 98% of desired porphyrin. HRMS-ESI m/z 746.6725 [M+H]; 
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calculated for C48H35N5O4 745.82. 1H NMR (400 MHz, CDCl3): d 4.25 (s, 2H), 4.38 (s, 2H), 
7.75-7.79 (m, 9H, m-, p-Ph-H), 8.20-8.14 (m, 8H, 6 o-Ph-H, 2 m-Ar-H), 8.31 (d, 2H, o-Ar-H, 
J=5.96 Hz), 8.84 (s, 4H, !-H), 8.89 (d, 2H, !-H, J=4.5 Hz). 13C NMR and absorbance spectra 
were identical to that presented in the literature.4  
Synthesis of 5-(4-methyoxycarbonylphenyl)-10,15,20-triphenylporphyrin (2-5): To a round 
bottom flask was added benzaldehyde (0.500 g, 3.0 mmol), methyl-4-formylbenzoate (0.387 g, 
1.5 mmol), and freshly distilled pyrrole (0.421 g, 4.0 mmol) under argon at room temperature. 
The mixture stirred for 10 minutes. BF3.Et2O was added (0.20 mL) and the reaction stirred for 2 
h. Argon was turned off and 400 mg of DDQ was added to reaction mixture. After stirring for 45 
minutes at room temperature, the solution was quenched with aqueous NaHCO3 until the 
aqueous layer was colorless (approx. 10-15 times). A silica plug was used to remove 
polymerized products. TLC was used to find the best solvent system. A final flash 
chromatography in Hexanes/DCM (3:7) was done to yield the mono-substituted methyl ester 
triphenylporphyrin in 9% yield. A deprotection of the methyl ester with 2 M NaOH (200 mL, 2.0 
mol) in DMF and subsequent acidification with 1 M HCl until pH 2.0, yielded porphyrin 2-5. 
HRMS-ESI m/z 659.2614 [M+H]+; calculated for C45H30N4O2 658.75. 1H NMR was identical to 
that in literature.20 
Synthesis of Porphyrin 2-6: To a solution of porphyrin 2-5 was added DIEA (0.3 mL, xs) and 2 
mL DMF.  Flask was sonicated to ensure porphyrin solubility.  After 5 minutes, HOBt (0.03076 
g, 0.07587 mmol) and TBTU (0.07312 g, 0.7587 mmol) were added to the flask.  The reaction 
stirred for 15 minutes.  Glycine tert-butyl ester hydrochloride (0.1178 g, 0.1138 mmol) was 
added to the flask.  The reaction was stirred at room temperature.  To remove DMF, the RBF 
was placed under high vacuum to remove residual DMF or co-evaporated with hexanes at 60oC.  
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Flash column chromatography was conducted using 50:50 EtAc: CH2Cl2 for elution and yielded 
90%. HRMS-ESI m/z 772.3282 [M+H]; calculated for C51H41N5O3 771.90. 1H NMR (400 MHz, 
CDCl3): d -2.76 (s, 2H), 1.60 (s, 9H), 4.11-4.15 (q, 1H, J=7.3 Hz), 4.33-4.34 (d, 2H, J=4.88 Hz), 
6.97-6.99 (t, 1H, J=4.88 Hz), 7.73-7.78 (m, 9H, m-, p-Ph-H), 8.21-8.24 (m, 8H, 6 o-Ph-H, 2 m-
Ar-H), 8.31 (d, 2H, o-Ar-H, J=5.96 Hz), 8.80 (s, 2H, !-H, J=4.8 Hz), 8.87 (s, 4H, !-H), 8.88 (d, 
2H, !-H, J=4.8 Hz).  13C NMR (400 MHz): 28.16, 42.75, 118.54, 120.37, 120.53, 125.48, 
126.73, 127.79, 133.32, 134.56, 134.71, 142.07, 145.86, 169.41, 169.47. UV-VIS (chloroform) 
"max (L mol!1 cm!1) 425 (195,600), 525 (17,100), 558 (12,200), 599 (10,200), 656 (8,200). 
 
Synthesis of Porphyrin 2-7: To deprotect 2-6, a solution of the tert-butyl protected porphyrin 
(0.200 g, 0.2591 mmol) in 3 mL of dichloromethane was added 4.25 mL of TFA (57.3598 
mmol), and the final mixture was stirred at room temperature for 4 h.  After removal of the 
solvent under vacuum overnight, the residue was triturated and washed with Et2O (3 times at 8 
minutes each, via centrifugation and decanting of ether) to afford porphyrin as a green solid in 
quantitative yield. Reaction product was used immediately for conjugation of the NH2-3PEG-tBu 
linker.  Proton NMR was conducted in deuterated acetone; ESI-MS conducted. HRMS-ESI m/z 
358.6380 [M+2H]2+, 716.2666 [M+H]+; calculated for C47H33N5O3 715.80. 1H NMR (400 MHz, 
(CD3)2CO): -2.81 (s, 2H), 4.02 (broad, 2H), 4.07-4.11 (q, 1H), 7.45 (broad t, 1H), 7.78-7.80 (m, 
9H, m-, p-Ph-H), 8.23-8.34 (m, 8H, 6 o-Ph-H, 2 m-Ar-H), 8.29-8.31 (d, 2H, o-Ar-H, J=5.96 Hz), 
8.88 ((broad) d, 8H, !-H). UV-VIS (chloroform) "max (L mol!1 cm!1) 425 (144,470), 523 






Figure 2.4. 1H NMR of Porphyrin 2-6. 



























































Figure 2.5. 13C NMR of Porphyrin 2-6. 











































































 Synthesis of 5-(4-(2-phenoxy)phenyl)-10,15,20-tris(4-hydroxyphenyl)porphyrin (2-9): To a 
round bottom flask was added 2-8 (0.600 g, 0.8837 mmol) and Cs2CO3 (0.533 g, 1.636 mmol) in 
anhydrous DMF or THF. This was stirred for 30 minutes before tert-butyl bromoacetate (0.319 
g, 1.636 mmol) was added. The flask was heated to 70oC and stirred for 4 hours before the 
solvent was evaporated and purified on normal-phase silica with DCM/EtAc (1.5:0.5). 
Recrystallization with DCM/Hexanes yielded 39% of 2-9. To deprotect 2-9, a solution of it 
(0.0251 g, 0.0266 mmol) in 3 mL of dichloromethane was added 3 mL of TFA and the final 
mixture was stirred at room temperature for 4 h.  After removal of the solvent under vacuum 
overnight, the residue was triturated and washed with Et2O (3 times at 8 minutes each, via 
centrifugation and decanting of ether) to afford porphyrin as a green solid in quantitative yield. 
MALDI-MS of 2-9 m/z 816.046 [M+Na], calculated for C50H40N4O6 792.88. 1H NMR (400 
MHz, CD3OD): 1.29 (s, 9H), 4.51 (s, 3H), 7.21-7.24 (d, 6H, o-Ph-H, m-Ar-H, J=8.5 Hz), 7.34-
Figure 2.6. 1H NMR of Porphyrin 2-7. 



























































7.37 (d, 3H, J=8.5 Hz), 8.01-8.03 (d, 6H, o-Ar-H, J=8.5 Hz), 8.12-8.14 (d, 2H, !-H, J=8.5 Hz) 
8.90 (m, 8H, !-H). 
Synthesis of Porphyrin 2-10: To deprotect 2-9, a solution of the tert-butyl protected porphyrin 
(0.200 g, 0.2591 mmol) in 3 mL of dichloromethane was added 4.25 mL of TFA (57.3598 
mmol), and the final mixture was stirred at room temperature for 4 h.  After removal of the 
solvent under vacuum overnight, the residue was triturated and washed with Et2O (3 times at 8 
minutes each, via centrifugation and decanting of ether) to afford porphyrin as a green solid in 
quantitative yield. Reaction product was used immediately for conjugation to the 3-PEG linker. 
MALDI-TOF-MS of 2-10 m/z 816.056 [M+Na]+, calculated for C46H32N4O6 736.77. 
Synthesis of 5-(4-methoxycarbonylphenyl)-10,15,20-tris(3,4,5-trimethoxyphenyl)porphyrin 
(2-11): To a round bottom flask was added 3,4,5-trimethoxybenzaldehyde (0.100 g, 6.0 mmol), 
methyl-4-formylbenzoate (0.097 g, 0.7 mmol), and freshly distilled pyrrole (0.023 g, 4.0 mmol) 
under argon at room temperature. The mixture stirred for 10 minutes. BF3.Et2O was added (0.01 
mL) and the reaction stirred for 2 h. Argon was turned off and 400 mg of DDQ was added to 
reaction mixture. After stirring for 45 minutes at room temperature, the solution was quenched 
with aqueous NaHCO3 until the aqueous layer was colorless (approx. 10-15 times). A silica plug 
was used to remove polymerized products. TLC was used to find the best solvent system. A final 
flash chromatography in hexanes/DCM/EtAc (1.5:1:1) was done to yield the mono-substituted 
methyl ester triphenylporphyrin in 9% yield. MALDI-MS m/z 943.802 [M+H]; calculated for 
C55H50N4O11 942.35. 
Synthesis of 5-(4-propargylphenyl)-10,15,20-tri(4-hydroxyphenyl)porphyrin (2-12): To a 
round bottom flask was added 2-8 (0.020 g, 0.0295 mmol) and Cs2CO3 (0.010 g, 0.0295 mmol) 
in anhydrous THF. Propargyl bromide (in 80% toluene) was added (0.0168 g, 0.118 mmol) and 
! 42 
the reaction proceeded for 2 h. The products were separated on column chromatography using 
CHCl3/Ethyl Acetate (8:2) with 35% yield. MALDI-MS m/z 717.028 [M+H]; calculated for 
C47H32N4O4; 1H NMR (400 MHz, MeOD): d -2.78 (s, 2H), 3.77 ppm (s, 1H, alkyne-H), 5.11 
ppm (s, 2H, CH2), 4.95 ppm (s, 3H, OH), 7.47-7.52 (m, 6H, m-Ph-H), 8.30-8.47 (m, 6H, o-Ph-H) 
8.79-8.81 ppm (m, 4H, m-, o-Ar-H), 8.97 ppm (m(s), 8H, !-H). 13C NMR (400 MHz, CDCl3): 
29.59, 56.28, 61.23, 112.88, 120.19, 127.87, 131.02, 131.19, 131.29, 131.65, 134.40, 137.39, 
137.79, 146.86, 151.33, 167.23. 
Synthesis of Porphyrin 2-13: To a solution of tert-butyl ester-deprotected porphyrin, 2-7 
(0.0064g, 8.95109E-06 mmol) in DMF (1 mL) was added DIEA (8.43188753E-06 g, 
5.3702629E-05 mmol, 0.011364 uL), HOBt (0.0012093 mg, 8.95109E-06 mmol), and TBTU 
(0.0028741 mg, 8.95109E-06 mmol).  The mixture was stirred for 5 minutes, then NH2-3PEG- 
tBu (0.0024826 mg, 8.95109E-06 mmol) was added, and stirring continued for 48 hours at room 
temperature.  Reaction was monitored via TLC after each 24 hour interval. The reaction mixture 
was diluted with 20 mL of ethyl acetate, washed with water (3 x 40 mL), and dried over 
anhydrous MgSO4.  Solvent was evaporated under vacuum. The target porphyrin was purified 
by flash chromatography on silica gel using 100% ethyl acetate for elution, yielding 40.3%-
60.1% of tert-butyl ester of porphyrin. HRMS-ESI m/z 975.8 [M+H]+, calculated for C60H58N6O7 
974.44. 1H NMR (400 MHz, CDCl3): d -2.78 (s, 2H), 1.46 (s, 9H), 2.53-2.57 (t, 2H, J=6.4 Hz), 
3.59-3.60 (m, 2H, J=4.0 Hz), 3.69 ((broad) m, 9H), 3.77-3.78 (t, 2H, J=6.4 Hz), 4.32-4.33 (d, 2H, 
J=4.84 Hz), 6.81-6.84 (m, 1H), 7.45-7.47 (t, 1H, J=4.0 Hz), 7.74-7.79 (m, 9H, m-, p-Ph-H), 8.21-
8.25 (m, 8H, 6 o-Ph-H, 2 m-Ar-H), 8.30-8.32 (d, 2H, o-Ar-H, J=5.96 Hz), 8.78-8.79 (d, 2H, !-H, 
J=4.3 Hz), 8.85-8.87 ((broad), m, 6H, !-H).  13C NMR (250 MHz, CDCl3): 28.00, 36.15, 39.49, 
43.36, 68.84, 69.57, 70.37, 70.54, 120.24, 125.50, 126.60, 127.66, 131.14, 133.11, 134.43, 
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134.54, 141.93, 145.70, 167.53, 168.81. UV-VIS (chloroform) "max (L mol!1 cm!1) 425 
(436,000), 524 (13,010), 557 (5000), 598 (1,100), 657 (100). 
Synthesis of Porphyrin 2-14: Deprotection of the tert-butyl group occurred in a solution of  
TFA (1 mL) and DCM (1 mL) for 4 hours. After removal of the solvent under vacuum overnight, 
the residue was triturated and washed with Et2O (3 times at 8 minutes each, via centrifugation 
and decanting of ether) to afford porphyrin as a green solid in quantitative yield. Conjugations to 
biomolecules continued. HRMS-ESI m/z 920.0213 [M+H]+, calculated for C56H50N6O7 919.03 
1H NMR (400 MHz, CDCl3): -2.75 (s, 2H), 2.53-2.56 (m, 2H), 3.46-3.50 (m, 2H), 3.59-6.63 
((broad) m, 9H), 3.72-3.75 (m, 2H), 4.22-4.24 (d, 2H, J=5.5), 7.52-7.54 (m, 1H), 7.84-7.87 (m, 
8H, m-, p-Ph-H), 8.26-8.27 (d, 8H, o-Ph-H, m-Ar-H, J=6.7 Hz), 8.39-8.40 (d, 2H, o-Ar-H, 
J=4.3), 8.42 ((broad) s, 1H), 8.88-8.90 (m, 8H, !-H). UV-VIS (chloroform) "max (L mol!1 cm!1) 
425 (183,450), 524 (12,075), 559 (7,925), 600 (6,550), 657 (5,875). 
Synthesis of 5-PEG 2-17: Hexaethylene glycol (0.847g, 3.00 mmol) and tert-butyl diazoacetate 
(0.217g, 2.00 mmol) were combined in dry DCM under nitrogen atmosphere.  Three drops of 
boron triflate diethyl etherate were added to the mixture.  The reaction was stirred for 15 
minutes.  After this time, another three drops of BF3-Et2O were added and the mixture was 
stirred for 15 minutes.  TLC was used to monitor the reaction. After reaction completion, 
reaction was diluted with ethyl acetate, washed with brine, and dried over anhydrous magnesium 
sulfate, dried and concentrated.  The reaction was submitted to ESI-MS to confirm presence of 
product. HRMS-ESI m/z [M+Na]+ 419.2233, calculated for C18H36O9 396.47. 
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Figure 2.6. ESI-MS of 2-17. 
Synthesis of 5-PEG 2-18: Crude 2-17 was co-evaporated with toluene.  Dry DCM was added to 
crude mixture.  Et3N (3.035 g, 30 mmol) and trimethylamine hydrochloride (0.1911 g, 2 mmol) 
were added to RBF.  Reaction flask was put in iced bath and temperature reached 0oC. Tosyl 
chloride was dissolved in vial with dry DCM. This mixture was added dropwise to RBF over 10 
minutes while the RBF remained in ice bath. The ice bath was removed after final addition of 
tosyl chloride (after 10 minutes).  Reaction mixture stirred for an additional 60 minutes at room 
temperature.  TLC was used to monitor the reaction. After reaction completion, the mixture was 
washed with 1 N H2SO4, aqueous NaHCO3, and aqueous NaCl.  Reaction was dried with 
MgSO4, filtered and concentrated.  The sample was continued to the next step without 
purification.  
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Synthesis of 5-PEG 2-19: The crude material 2-18 was co-evaporated with toluene (3x50 mL) 
and stirred under reflux with sodium azide (0.06501 g, 1 mmol) in DMF (1 mL) for 2.5 hours at 
110oC. Reaction was brought to room temperature.  The mixture was taken up in ethyl acetate 
(2x50 mL) washed with brine (3x50 mL), dried with MgSO4, filtered, and concentrated. HRMS-
ESI m/z 367.37 [M-tButyl]+, 446.2088 [M+Na]+, calculated for C18H35N3O8 421.49. 
 
Figure 2.7. ESI-MS of 2-19. 
Synthesis of 5-PEG 2-20: Crude material 2-19 was dissolved in ethanol: chloroform (10:1 mL). 
Palladium 10 wt. percent on carbon (100 mg) was added to RBF under hydrogen atmosphere for 
12 hours.  The catalyst was removed by filtration over celite and filtrate was concentrated. 
Residue was taken up in ethyl acetate (70 mL) and extracted with potassium hydrogen sulfate (1 
N, 1x100 mL, 2x50 mL).  Aqueous layers were combined and made caustic with sodium 
carbonate.  These layers were then extracted with chloroform (1x100 mL, 2x50 mL), dried with 
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MgSO4, filtered via gravity filtration, then concentrated to give the product.  ESI-MS was used to 
observe presence of product. HRMS-ESI m/z 396.259 [M+H]+, calculated for C18H37NO8 
395.49. 
 
Figure 2.8. HRMS ESI of 2-20. 
Synthesis of 5-PEG 2-21: Hexaethylene glycol (0.1483 g, 0.504 mmol) and dry DCM were 
added to RBF.  Triethylamine (101.19 g, 1.008 mmol) and trimethylamine hydrochloride 
(0.09557 g, 1.00 mmol) were added to RBF.  Reaction flask was put in ice bath and temperature 
reached 0oC. Tosyl chloride was dissolved in vial with dry DCM. This mixture was added 
dropwise to RBF over 10 minutes while the RBF remained in ice bath. After the last drop was 
added, the ice bath was removed.  Reaction was monitored via TLC every 10 minutes or until 
initial formation of the monosubstituted product was formed. After reaction completion, the 
reaction mixture was washed with H2SO4 (1 N, 2x50 mL), saturated NaHCO3 (1x100 mL), and 
! 47 
brine (1x70 mL).  Organic product was dried with anhydrous MgSO4, filered, then concentrated.  
The sample was continued to the next step without purification. ESI-MS m/z 533.2935 [M+2K]+, 
592.3044 [M+3K+Na]+, calculated for C19H34O10S 454.53. 
 
Figure 2.9. ESI-MS of 2-21. 
Synthesis of 5-PEG 2-22: Crude compound 2-21 (0.870 mg) was combined with 4 mL dry DMF 
and NaN3 (0.1950 mg, 3 mmol).  The reaction mixture was heated to 100oC for 2.5 hr, then 
cooled to room temperature. The mixture was taken up in ethyl acetate (2x50 mL) washed with 
brine (3x50 mL), dried with MgSO4, filtered, and concentrated.  Sample was submitted to ESI-
MS for analysis. HRMS-ESI m/z 308.1807 [M+Na]+, calculated for C12H35N3O6 307.34. 
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Figure 2.10. ESI-MS of 2-22. 
Synthesis of 5-PEG 2-23: Immediately following crude production of 2-17, to dry DCM (10 
mL) was added in order: triphenylphosphine (0.8993 g, 3.429 mmol), imidazole (0.2334 g, 3.429 
mmol), and iodine (0.4381 g, 3.429 mmol).  A solution of the alcohol, 7, in 7 mL of dry DCM 
was added and the mixture was stirred at room temperature for 2 hours.  The solvent was 
removed in vacuo, then resuspended in DCM.  To remove the iodine, a small silica plug was 
sued.  The crude product was obtained as a yellow oil. TLC was used to monitor the reaction.  
ESI-MS was used to observe presence of product. HRMS-ESI m/z 529.13 [M+Na]+, calculated 
for C18H35IO8 506.37. 
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Figure 2.11. ESI-MS of 2-23. 
2.8 References 
1. Adler, A. D.; Longo, F. R.; Finarelli, J. D.; Coldmacher, J.; Assour, J.; Korsakoff, 
L., A simplified synthesis for meso-tetraphenylporphine. Journal of Organic Chemistry 1967, 32 
(2), 476. 
2. Lindsey, J. S.; Schreiman, I. C.; Hsu, H. C.; Kearney, P. C.; Marguerettaz, A. M., 
Rothemund and Adler-Longo reactions revisited: synthesis of tetraphenylporphyrins under 
equilibrium conditions. Journal of Organic Chemistry 1987, 52 (5), 827-836. 
3. Vicente, M. G. H.; Smith, K. M., Porphyrins and Derivatives Synthetic Strategies 
and Reactivity Profiles. Curr. Org. Chem 2000, 4, 139-174. 
4. Luguya, R.; Jaquinod, L.; Froncek, F. R.; Vicente, M. G. H.; Smith, K., Synthesis 
and reactions of meso-(p-nitrophenyl)porphyrins. Tetrahedron 2004, 60, 2757-2763. 
5. Sibrian-Vazquez, M.; Hao, E. H.; Jensen, T. J.; Vincente, M. G. H., Enhanced 
cellular uptake with a cobaltacarborane-porphyrin-HIV-1 Tat 48-60 conjugate. Bioconjugate 
Chem. 2006, 17 (4), 928-934. 
! 50 
6. Flessner, T.; Doye, S., Cesium carbonate: A powerful inorganic base in organic 
synthesis. J. Prakt. Chem.-Chem. Ztg. 1999, 341 (2), 186-190. 
7. Pearson, R. G., Hard and Soft Acids and Bases. JACS 1963, 85, 3533-3539. 
8. (a) Gazit, A.; Yaish, P.; Gilon, C.; Levitski, A. J., Tyrphostins I: synthesis and 
biological activity of epidermal growth factor receptor. Journal of Medicinal Chemistry 1989, 
32, 2344-2352; (b) Kamath, S. B., J. K., Receptor-Guided Alignment-Based Comparative 3D-
QSAR Studies of Benzylidene Malonitrile Tyrphostins as EGFR and HER-2 Kinase Inhibitors. 
Journal of Medicinal Chemistry 2003, 46, 4657-4668; (c) Kamath, S.; Buolamwini, J. K., 
Targeting EGFR and HER-2 Receptor Tyrosine Kinases for Cancer Drug Discovery and 
Development. Medicinal Research Reviews 2006, 26 (5), 569-594. 
9. Lindsey, J. S., Synthesis of meso-Substituted Porphyrins. In The Porphyrin 
Handbook, Academic Press: San Diego, 2000; Vol. 1. 
10. (a) Kolb, H. C.; Finn, M. G.; Sharpless, K. B., Click Chemistry: Diverse 
Chemical Function from a Few Good Reactions. Angew. Chem. Int. Ed. 2001, 40, 2004-2021; (b) 
Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B., A Stepwise Huisgen 
Cycloaddition Process: Copper(I)-Catalyzed Regioselective "Ligation" of Azides and Terminal 
Alkynes. Angew. Chem. Int. Ed. 2002, 41 (14), 2596-2599. 
11. Hao, E. H.; Jensen, T. J.; Vicente, M. G. H., Synthesis of Porphyrin-Carbohydrate 
Conjugates Using “Click” Chemistry and Their Preliminary Evaluation in Human HEp2 Cells. 
Journal of Porphyrins and Phthalocyanines 2009, 13 (1), 51-59. 
12. Van der Broek, F. J. C.; Fockens, P.; Dekker, E., New Developments in Colonic 
Imaging. Aliment Pharmocology Ther. 2007, 26, 91-99. 
13. Li, J.; Kao, W. J., Synthesis of Polyethylene Glycol (PEG) Derivatives and 
PEGylated!Peptide Biopolymer Conjugates. Biomacromolecules 2003, 4, 1055–1067. 
14. Sibrian-Vazquez, M.; Jensen, T. J.; Hammer, R. P.; Vicente, M. G. H., Peptide-
mediated cell transport of water soluble porphyrin conjugates. J. Med. Chem. 2006, 49, 1364-
1372. 
15. Hollingsworth, J. V.; Richard, A. J.; Vicente, M. G. H.; Russo, P. S., 
Characterization of the Self-Assembly of meso-Tetra(4-sulfonatophenyl)porphyrin (H2TPPS4–) 
in Aqueous Solutions. Biomacromolecules 2012, 13, 60-72. 
16. Sibrian-Vazquez, M.; Jensen, T. J.; Vicente, M. G. H., Porphyrin Retinamides: 
Synthesis and Cellular Studies. Bioconjugate Chem. 2007, 18, 1185-1193. 
17. Thumshirn, G.; Hersel, U.; Goodman, S. L.; Kessler, H., Multimeric Cyclic RGD 
Peptides as Potential Tools for Tumor Targeting: Solid-Phase Peptide Synthesis and 
Chemoselective Oxime Ligation. Chem, Eur. J. 2003, 9, 2717-2725. 
! 51 
18. Fu, X.; Zhang, S.; Yin, S.; McAllister, T. L.; Jiang, S. A.; Tann, C.-H.; 
Thiruvengadam, T. K.; Zhang, F., Tetrahedron Letters 2003, 43, 573-576. 
19. (a) Lange, G. L.; Gottardo, C., Facile conversion of primary and secondary 
alcohols to alkyl iodides. Synth. Comm. 1990, 20, 1473-1479; (b) Langer, F.; Puntener, K.; 
Sturmer, R.; Knochel, P., Preparation of Polyfunctional Phosphines using Zinc Organometallics. 
Tetrahedron: Asymm. 1997, 8, 715-738. 
20. Vermathen, M.; Louie, E. A.; Chodosh, A. B.; Ried, S.; Simonis, U., Interactions 
of Water-Insoluble Tetraphenylporphyrins with Micelles Probed by UV!Visible and NMR 




CHAPTER 3. BENZYLIDENEMALONONITRILE- AND QUINAZOLINE-BASED 
PORPHYRIN CONJUGATES 
 
3.1 The Development of Small Tyrphostin Ligands with Affinity for EGFR 
Tyrphostins are a class of molecules that were developed to inhibit functions of EGFR, a 
member of the tyrosine kinase family.2 The tyrosine kinases are important in cellular regulation 
by phosphorylating tyrosine residues or any exogenous substrates for the kinase.2 If there are 
problems in cell signaling of a tyrosine kinase, this often renders the kinase hyperactive, 
implicating these proteins in illnesses such as CRC, psoriasis, non-small cell lung cancer 
(NSCLC), chronic myeloid leukemia, gastrointestinal stromal tumors, acute kidney failure, and 
even septic shock.3 Much work has been conducted on most of the tyrosine kinases, including 
EGFR, through extensive characterization1b and development of small molecules to prevent 
their hyperactivity.2, 4 Tyrphostins (TYRosine PHOSphorylation Inhibitors) specifically inhibit 
phosphorylation of the receptor, which is believed to be the first step in signal transduction 
across the plasma membrane.2 Subsequently, messages are sent to inner cytoplasmic enzymes 
that are affiliated with the receptor.4k The accuracy of this process is dependent upon the 
continuity of each messenger, or enzyme, to deliver the correct message. Over-expression of 
EGFR or any other tyrosine kinase is caused by one mutation, which delivers a persistent, 
sustained signal, leading to amplification of that receptor.4k Therefore, it is believed that if this 
initial step is regulated, over-expression of the receptor should cease.4o  This concept has 
become a modality for developing molecules to impede over-expression using specifically 
designed inhibitors that may be effective in two ways; the inhibitors will competitively inhibit 
phosphorylation by binding to the ATP site or they may compete with various substrates which 
become phosphorylated through the process of cell signaling.4a, 4k, 5 Gazit and Levitzki are 
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recognized for coining the term “tyrphostins,” but also devising a name for this design 
methodology – “signal transduction therapy.”4k, 5 The initial inhibitors were designed from 
natural flavones, isoflavones, ansamycins and epidithiodioxopiprazines.4k, 4m This list includes 
the molecules erbstatin (Figure 3.1a), which is the most notable of these compounds, as well as 
genistein (Figure 3.1b), quercetin (Figure 3.1c), lavendustin A, and luteolin.4k, 4m These natural 
compounds were found to be unspecific for only one type of protein tyrosine kinase (PTK) 
family member (each inhibited multiple PTKs, which would increase cytotoxicity),4k, 4m have 
low potencies,4k and in many cases, are considered difficult to synthesize synthetically.6 
Tyrphostins, however, have shown great promise as selective inhibitors for EGFR.  Their 
selectivity varies, with some molecules having affinity for the ATP site, while others are 
substrate-competitive inhibitors.  In any case, these molecules could potentially serve as ligands 
conjugated to porphyrins to improve current in vivo imaging agents.  
  
In designing new in vivo imaging agents, it is important to note some clinical results of 
the successful EGFR-targeted agents in order to further illustrate their potential efficacy.  
Results of orally administered tyrphostins used in conjunction with intravenously administered 
monoclonal antibodies (mAbs) illustrate that some have achieved marketability 
(vandetanib/Capresa),7 while others are still undergoing clinical trials.7a, 8 Several issues arise in 



















Figure 3.1. Structures of Erbstatin (3.1 a), Genistein (3.1 b), and Quercetin (3.1 c). 
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that their water-solubility is low and have increased potency.7a  Additionally, in order to achieve 
the highest rate of affinity for EGFR over-expressing tumors, these tyrphostins must be used 
with another method of treatment.7b Also, in terms of tyrphostin specificity for the ATP site or 
as a substrate-competitive molecule, another consideration must be made. It is known that most 
tyrosine kinase inhibitors, like tyrphostins, target the ATP-binding site, which is known as a 
“Type 1” inhibitor.1c This is the most common type of tyrphostin that has been developed to 
date and gives the structural basis for how our molecules (BMN- and quinazoline-based 
porphyrin conjugates) were designed (Figure 3.2 a, b). While this may be a promising approach 
for developing tyrphostin-based agents, the tyrosine kinase family is comprised of over 500 
different species, yet the ATP-binding site is conserved in most of these kinases.4k, 7b Therefore, 
in order to achieve specific binding of tyrphostins at the ATP site, higher dosages of the 
tyrphostin must be administered, which subsequently increases cytotoxicity levels.4k, 7b Other 
classes of tyrphostin-based molecules have been developed, however, that give alternative 
methods to treat EGFR over-expressing cancers. The “Type 2” inhibitors have an affinity for 
EGFR in its “inactive conformation,” or when it has not homo- or hetero-dimerized with 
another receptor.1c  Allosteric tyrphostin inhibitors do not actually bind at the ATP site of 
EGFR, but usually at a site close to this area.1c  The allosteric type tends to be more specific for 
each EGFR family member. EGFR is responsible for cell proliferation and each EGFR family 
member has a specific signal that it sends to the nucleus, which differentiates it from its other 
members. There are also tyrphostins that interact covalently within the ATP site, causing 
irreversible inhibition.  These molecules, however, might be too toxic for human use.1c The low 
IC50 values of tyrphostins suggest higher affinity of a tyrphostin for cells that over-express 
EGFR. Current in vivo imaging agents are particularly ineffective due in part to their high 
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cytotoxicity and lack of tumor cell specificity. These facts have brought great insight to the 
design of our porphyrin-based tyrphostin conjugates, which should lead to a balance of 
lipophilic and hydrophilic properties as well as a high specificity for CRC, which is necessary 
for an improved in vivo imaging agent.  
To synthesize a highly specific, porphyrin-based tyrphostin conjugate as a potential in 
vivo imaging agent, two types of tyrphostin molecules were synthesized: one ring-BMNs, which 
have the scaffold illustrated in Figure 3.2 a, and two ring quinazolines, shown in Figure 3.2 b. 
The importance of key hydrogen bonding, electrostatic and hydrophobic interactions of BMNs 
and quinazolines with EGFR have been considered using the crystal structure of EGFR obtained 
by Stamos, et al.1 Positions R1 and R2 of the benzene ring of the BMNs (Figure 3.2 c) are 
substituents that are located in the “Solvent Accessible Area.”1b One cyano group of 
malononitrile or cyanoacetamide (at position R3) hydrogen bonds with a water molecule located 
near “Hydrophobic Pocket II” next to residue Thr766.1a Conversely, binding of the quinazoline 
(Figure 3.2 d) at the EGFR ATP site shows N1 hydrogen bonding interactions with Met769,1c, 9 
while N3 hydrogen bonds with a water molecule located near residue Thr766.1b The R1 group 
on the aniline of the quinazoline can vary (Br, Cl, methyl), although binding activity varies with 
each change of substituent at position R1 in different EGFR kinases.9 The groups at R1 direct the 
aniline ring of the quinazoline into “Hydrophobic Pocket II.”1b While substituents labeled as R2 
and R3 may also vary, these positions of the quinazoline (positions 6 and 7, as labeled in Figure 




Figure 3.2. BMN Scaffold (3.2a), Quinazoline Scaffold (3.2b), Potential Binding of BMN 
(3.2c) or Quinazoline (3.2d) in ATP active site (inspired by Stamos et al, Kamath et al, and 



















R1 = -CN, -CONH2
R2 = -H, -OH
R3 = -H, -OH
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R1 = -Br, -Cl, -CCH
R2 = -OMe, -OH, -2PEG, -NH2






































































3.2 Description of Benzylidenemalononitriles (BMNs) 
Gazit and colleagues designed the initial BMN tyrphostins after developing a molecular 
platform based on erbstatin (Figure 3.1 a).2-3, 4k, 4o Erbstatin was first isolated from an 
actinomycete by Umezawa et al in the mid-1980s.4n The BMN was one of the main scaffolds of 
the “first generation” of tyrphostins.2, 4n BMNs are a combination of tyrosine and erbstatin, 
which are both phenolic molecules and also contain two additional carbons on one side of the 
phenol.2 The basic pharmacophore in the “first generation” tyrphostins is shown in Figure 3.3, 
the malononitrile moiety. According to Gazit, two cyano substituents were found to increase the 
biological activity of all the tyrphostin compounds.2  Many tyrphostins have been studied. For 
example, tyrphostins AG18 and AG82 both showed high affinity for EGFR and low IC50 values 
in EGFR over-expressing cells.2 This shows that the malononitrile moiety is important for the 
activity of BMNs and their derivatives.  However, the rationale behind this substituent’s activity 
has not been completely determined. Scientists have proposed that due to the large 
electronegativity of the cyano (CN) group alone, it can be considered a “pseudohalogen,” or a 
molecule that behaves in the same way that a halogen would (e.g. inductively electron-
withdrawing and is relatively higher in electronegativity compared to other groups).  Halogens, 
however, are pi-donors, while the CN groups are not, and actually tend to act more like aryl 
groups (extending the pi-systems).10 A thorough discussion of the relative activities of BMNs in 
comparison with quinazoline tyrphostin derivatives will be presented in Section 3.5.  In any 
case, the BMN family contains substituents that clearly impact the affinity of this molecule for 
the ATP site of EGFR.  Many of the BMNs are commercially available, such as those shown in 
Figure 3.4, however, a group (such as an amino group must be introduced for conjugation to a 
carboxylic acid-terminated porphyrin. 
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         3.2.1 Synthesis, Characterization, and Cell Studies of BMN 
Synthesis of BMN 3-3 consisted of a Knoevenagel condensation of 4-
aminobenzaldehyde with malononitrile or cyanoacetamide in EtOH.11  A small amount of 
piperidine was used to catalyze the condensation, yielding bright yellow crystals.  However, 
while the reaction is well known and simple to accomplish, the target product (3-3) was only 
obtained in low yields containing mainly starting material, according to NMR, MS, and x-ray 
crystallography.  Therefore, another starting material was used, 4-nitrobenzaldehyde (3-1).  In 
this case, the nitro group was reduced to an amine group and the aldehyde was converted to a 
malononitrile (3-3) or cyanoacetamide (3-6); both of these functional groups have been 
implicated as moieties that have high affinity for EGFR.2  After reduction of the nitro group to 
the amine, the molecule was conjugated to a carboxylic acid-terminated PEG to yield 3-4.  This 
process, however, also gave very low yields and the reaction mixture was difficult to purify.  
However, from mass spectrometry analysis, it was observed that the crude product was 
synthesized, and by TLC, a band illustrating a lower polarity than the BMN yet higher than the 
free PEG suggesting that the product was obtained (Scheme 3.1 a, b). It is important to note 
Figure 3.3. Pharmacophore Moiety of Tyrphostin BMNs. 
(a) Tyrphostin AG18 
(IC
50
 = 35 µM) 
(b) Tyrphostin AG82 
(IC
50
 = 3 µM)  
Figure 3.4. Structures of Tyrphostins AG18 (3.4 a) and AG82 (3.4 b). 
! 59 
that product 3-5 obtained significantly different yields than 3-2 via the typical Knoevenagel 
condensation reagents (the electron deficient cyano reagent in combination with the aldehyde, 
3-1). Compound 3-5 was obtained in much higher yield using urea (10 mol%) as catalyst. The 
lower yield obtained from the initial Knoevenagel condensation conditions for compound 3-5 
may have occurred due to the fact that there is a potential for 3-5 to form both the E and Z 
isomers, although the Z isomer should be more favorable, due to the presence of the bulky 
aromatic group on one side of the double bond.  Using urea as the catalyst in solvent-free 
conditions gives higher product yields. The urea can be washed away in water, therefore 







































































Because of the importance of the malononitrile functionality, we investigated whether 
this functional group alone and attached to a porphyrin could yield a conjugate that had affinity 
for EGFR.  The synthesis of this molecule is illustrated in Scheme 3.2.  Previously, a porphyrin 
was synthesized containing the PEG linker described in Chapter 2 (porphyrin 2-14).  Porphyrin 
2-14 was first solubilized in dry DCM then Et3N was added. The temperature of the solution 
was brought down to 0oC and TMSBr was added to facilitate formation of the silyl ester 
intermediate. Formation of the silyl ester was observed by TLC. The reaction temperature was 
then decreased to -78oC then subjected to reduction with 1 equivalent of DIBAL-H for 
approximately 3 minutes.13 Formation of the aldehyde was observed by TLC and ESI-MS, 
however, most of the product was reduced to the alcohol, resulting low yields of the target 
aldehyde. The aldehyde-terminated porphyrin was then subjected to the Knoevenagel 
condensation described previously (Scheme 3.1). TLC confirmed the aldehyde was converted 





Scheme 3.2. Synthesis of Malononitrile-terminated Pegylated Porphyrin. 
1. TMSBr, Et3N
DCM, 0oC
2. DIBAL-H (1 equiv.) 
























    EtOH, RT, 18h
               (5%)
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To observe the efficacy of this molecule in cells, 3-7 was added to HEp2 cells (human 
epidermoid carcinoma, and larynx cancer cell line)14 by Dr. Xiaoke Hu. HEp2 cells were plated 
onto glass chamber slides and were exposed to 10 !M of conjugate 3-7 over 18 h. Cell cultures 
were supplemented with organelle markers for endoplasmic reticulum (ER-Tracker Blue-White 
DPX, purchased from Molecular Probes, Figures 3.5 c, d), lysosomes (LysoSensor DND-189, 
purchased from Molecular Probes, Figures 3.5 e, f), mitochondria (MitoTracker Green FM, 
purchased from Molecular Probes, Figures 3.5 g, h), and Golgi network (BODIPY FL C5-
ceramide, purchased from Molecular Probes, Figure 3.5 i, j). Phase-contrast microscopy15 (as 
well as an overlay) was used to view the porphyrin in cells (Figures 3.5 a, b). Following 
incubation, the cells were washed 3 times with PBS and live-imaged using a Zeiss Axiovert 200 
fluorescence microscope fitted with a Texas Red filter set (to capture porphyrin conjugate 
fluorescence), an FITC filter set (to capture MitoTracker and LysoSensor probes), and a DAPI-
compatible filter set (to capture ER-Tracker probes). The images were acquired with a Zeiss 
Axiocam MRM CCD camera fitted to the microscope. Conjugate 3-7 localized primarily in the 
lysosomes (Figures 3.5 e, f), which is an important target for porphyrin-based medicinal 
agents.16  Future studies will include conducting the Knoevenagel condensation alone with the 
acid without the reduction to aldehyde.  The molecule produced will serve as a comparison to 





Figure 3.5. Subcellular 
Localization of Conjugate 3-7.  
 
Description of 
Fluorescent Dyes:  
(a) phase contrast, 
(b) overlay of compound and 
phase contrast, 
(c) ER tracker fluorescence, 
(d) overlay of organelle tracer [c] 
with compound fluorescence 
(e) LysoSensor Green 
fluorescence, 
(f) overlay of organelle tracer [e] 
with compound fluorescence 
(g) MitoTracker Green 
fluorescence, 
(h) overlay of organelle tracer [g] 
with compound fluorescence 
(i) BODIPY FL C5-Ceramide,  
(j) overlay of organelle tracer [i] 
with compound fluorescence. 
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3.3 Description of Quinazolines 
The first description of quinazolines emerged from Gazit et al in 1996, after extensive 
work on the BMNs. This scaffold was developed to compare monocyclic compounds to  
bicyclics, which are more rigid in structure.4f However, the work of chemists at Parke-Davis 
Pharmaceuticals (now a subsidiary of Pfizer, Inc.) brought the synthesis of the quinazolines to 
light with the preparation of PD153035 (Figure 3.6 a), a highly potent inhibitor of EGFR over-
expressing cells.17 The molecules designed in this work are derivatives of PD153035.  Based on 
the design shown in Figure 3.6 a, we synthesized a porphyrin conjugate containing the bicyclic 
structures shown in Figure 3.6 (b, c). These molecules were also investigated computationally 
to assess their potential binding at the ATP active site of EGFR. 
3.3.1 Synthesis and Characterization of Quinazolines 
Based on work published from chemists at Parke-Davis Pharmaceuticals,4b, 17a we 
synthesized the quinazoline through the pyrimidine ring because: 1) The synthesis was simple 
and previously described; a short linker was added to the pyrimidine ring and then the porphyrin 
was easily conjugated at its terminal carboxylic acid;4b 2) It was illustrated that hydrophilic 
methoxy groups proved to increase affinity for the active site compared with other quinazoline 
derivatives;4b, c, 17a and 3) The importance of the pyrimidine nitrogen at position 1, as well as the 



















Figure 3.6. Structure of PD153035 (a), Synthesis of Quinazoline through Pyrimidine (b), 
Synthesis of Quinazoline through Phenyl (c). 
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pegylated porphyrin (2-14) would favor solubility in aqueous solutions, decrease aggregation, 
and have favorable conformation for interaction with the receptor.1c, 4b, 4e, 17b However, the task 
of this synthesis and purifications proved to be quite difficult. Scheme 3.3 shows the 
methodology used for the quinazoline synthesis.  Beginning with the anthranilic acid 3-8, 2-
amino-4,5-dimethoxybenzoic acid, a heat catalyzed cyclization with formamidine hydrochloride 
occurred to yield 3-9 in 70% yield.4b  A Vilsmeier reaction with oxalyl chloride with 3-9 
yielded 3-10 in 97% yield. Compound 3-10 was subjected to two methods to yield the final 
quinazoline, 3-12.  First, 3-10 was subjected to a simple nucleophilic substitution with N-Boc 
ethylenediamine.  However, after changing the solvents (2-propanol, DMF, and toluene), 
varying the temperature (25oC-70oC), and duration of the reaction (1h-48h), only a crude 
mixture containing the product in low yield was achieved, as illustrated by ESI-MS analysis. 
Purification on silica gel chromatography was unsuccessful, despite using several eluants and 
separations in varying ratios of eluants.  Therefore, an alternative route was developed.  Using 
3-10, free ethylenediamine was added to the reaction mixture to achieve the product, 3-12.  This 
synthesis also proved to be difficult.  Solvents (DMF, toluene), temperatures (25oC-60oC), and 
duration of the reaction (1h-48h) were varied.  The best combination of variables yielded 30% 
of 3-12, in DMF at 60oC for 1 h.  Increasing the reaction time did not increase the yield. The 
crude was analyzed by ESI-MS, purified by silica gel column chromatography, followed by 
purification by HPLC using a gradient of MeOH and water.  The product (3-12) after HPLC, 
gave 30% yield of a brown solid.  
After characterization of 3-12 by use of MS and NMR, it was then conjugated to 
porphyrin 2-14, using typical peptide coupling conditions, DIEA/HOBt/TBTU, for two days in 
DMF. However, the yield after purification by silica gel column chromatography was low.  The 
! 65 
product was purified using varying solvent gradients in this order: EtAc (80%)/DCM 
(10%)/MeOH (10%), EtAc (70%)/iPrOH (30%), EtAc (60%)/iPrOH (40%), 
EtAc/CHCl3/MeOH (1:1:0.1), EtAc/CHCl3/MeOH/iPrOH (1:1:0.1:0.1), 
EtAc/CHCl3/MeOH/iPrOH (1:1:0.1:0.2). Approximately 35 fractions were collected and 
analyzed by TLC.  One of the later fractions (#24) contained the product and did not contain 
any additional spots on the TLC. While this proved to be quite challenging, the product was 
obtained, although in moderate yield (16%). Compound 3-13 was identified by UV-VIS and 
mass spectroscopy, and proton NMR.  This synthesis is being repeated to optimize yield. 
Methods have been developed to increase the yield of 3-13, such as using DMSO as the solvent 
for the synthesis of 3-12, as well as conjugating 3-12 to the Fmoc-3PEG (shown in Scheme 3.1) 
before conjugation to a carboxylic acid-terminated porphyrin (2-7). 
Because of the challenges encountered in the synthesis of conjugate 3-13, another 
quinazoline, 3-19, was prepared to allow for conjugation of porphyrin 2-14 to the quinazoline 
through its phenyl ring (Scheme 3.4). Figure 3.8 illustrates the structure of this porphyrin 
conjugate, 3-19, which, in comparison to PD153035, is similar.! !Beginning with anthranilic 
acid, 3-14, a similar heat catalyzed cyclization with formamidine hydrochloride took place to 
yield 60% of 3-15.  A Vilsmeier reaction with oxalyl chloride occurred to give 3-16 in 50% 
yield. Compound 3-17 was synthesized using 3-bromoaniline in basic conditions (Cs2CO3) and 
under reflux for 1 h to yield 40% of product. The nitro group at position 7 of the quinazoline 
was reduced using same procedure illustrated in Scheme 3.1, by using SnCl2 and HCl under 
reflux for 12 h to yield 42% of target quinazoline 3-19. The products in Scheme 3.4 were 
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Scheme 3.4. Synthesis of Quinazoline 3-18. 
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3.4 In Silico Studies on Tyrphostin-Based Porphyrin Conjugates 
BMN- and quinazoline-based porphyrin conjugates were subjected to computational 
calculations, more specifically, through molecular docking. While ab initio predictions can give 
insight toward the overall electronic properties of our molecules, it is not advantageous to 
conduct quantum mechanics (QM) calculations on large porphyrin conjugates because these are 
computationally expensive.18  Although QM is more accurate in terms of determining energy 
conformations, molecular mechanics (MM) methods, approximate energy/geometry 
values/conformations, resulting in faster computational determinations of lowest energy 
conformations.18 This section presents an analysis of tyrphostin molecules and their porphyrin 
conjugates as rationale for these molecules to be used as in vivo imaging agents for EGFR over-
expressing CRC.  
3.4.1 Molecular Mechanics and Docking of Tyrphostin-Based Porphyrin 
Conjugates 
 
Porphyrin-tyrphostin conjugate affinity for the EGFR active site was investigated by 
first, optimizing the geometry of the conjugate using MM2 employed in ChemBio3D19 or 
MacroModel,20 and then, subjected to Vina for docking. For this study, the large size and 
potential interactions of the porphyrin-tyrphostin conjugates was minimized before preparing 




















Figure 3.8. Structure of Conjugate 3-19. 
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energy minimization was conducted using MM2 method (vacuum) in MacroModel20 or Chem 
Bio 3D19 software.  The criteria for these calculations are listed in Table 3.1. The MM2 method 
is used for energy and geometry optimization of organic molecules, especially due to the fact 
that ab initio methods for this large molecule takes substantial computer time.18 
Table 3.1. Molecular Study Generation – Part 1 
Parameter Value 
Force Field MM2 
Max. No. of Iterations 10,000 
Convergence Criteria 0.01 cal/mol Å 
Dielectric Constant 1 (for vacuum) 
  
After obtaining the optimized conformers, AutoDock Vina21 (noted as “Vina”) was 
employed.  Vina has become of great use to many non-theoreticians because of its ease of use, 
lower computational time, and accessibility. Rather than use a force field such as AMBER,22 
which is employed in AutoDock 4,23 another is considered in Vina – an empirical free energy 
force field, which is essentially the summation of free energies from its dispersion forces 
(!Ggauss), repulsion forces (!Grepulsion), hydrogen bonding (!Ghbond), hydrophobic interactions 
(!Ghydrophobic), and lastly, the number of torsions (!Gtors).21 Improper consideration of the 
ligand’s orientation, location, and conformation can impact the overall calculation in terms of 
time and resulting conformations.  However, certain precautions were taken for computational 
studies with porphyrin-tyrphostin conjugates in Vina.  First, the “search space”21 was restricted 
to the EGFR ATP site to minimize computational time. Literature illustrates that the space of 
the ATP site of EGFR is located at the 760-800 numbered residues.1b  A search space of only 28 
x 24 x 22 Å was used to restrict the conjugated tyrphostin within the “search space.” A test 
! 69 
calculation was conducted to assess the viability of Vina for calculations. The crystal structure 
of EGFR (PDB ID: 1M17), which contains the ligand, erlotinib (Figure 3.9 a) was obtained 
from the Protein Data Bank. The erlotinib ligand was removed from the EGFR ATP site using 
AutoDockTools.21, 23 An MM2 energy minimized structure of erlotinib was docked using Vina. 
The third conformer obtained from Vina was less than 5 Å in from each hydrogen bond length 
compared to the original erlotinib ligand (Figure 3.11 a) crystallized with EGFR,1b with a 24% 
increase in hydrogen bond distance at the aniline bromine of erlotinib with Thr766 (from 4.85 Å 
to 5.33 Å) and a 10% increase in hydrogen bond distance at N1 position of the quinazoline with 
Met769 (from 3.53 Å to 4.36 Å), compared to literature distance values at these sites.1b The 
other eight (8) conformers of the erlotinib test screen in Vina were unfavorable in relation to 
1M17. The results of this test calculation are listed in Table 3.2 and presented in Figures 3.9 
(b, c, d).  
With promising results from the test calculation of the quinazoline, erlotinib (Figure 3.9 
a) in Vina, porphyrin-tyrphostin conjugates (3-4a, 3-6a, 3-7, 3-13, 3-19) were first, minimized 
using MM2 in MacroModel,20 then docked in Vina. For each porphyrin-tyrphostin conjugate, 
the number of rotatable bonds changed depending on the terminal ligand (see Table 3.4, column 
2). The search space remained the same (28 x 24 x 22 Å). The average computational docking 
time was approximately 6.5 hours for each porphyrin-tyrphostin conjugate. PyMol was used to 
visualize molecules and their lowest energy conformations in EGFR.24 
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  The docking results of the two BMN-based porphyrin conjugates (3-4a and 3-6a) gave 
significant insight toward understanding the potential of these molecules to bind at the ATP site 
of EGFR (Figures 3.10 and 3.11).  The conformation of conjugate 3-4a (Figure 3.10 a) 
illustrates that the structure of this conjugate is constrained. The phenyl ring of the terminal 
BMN is far from the porphyrin, suggesting potential pi-interactions may not be a problem for 
binding to the ATP site.  However, the placement of the conjugate is not in alignment with the 
(1) 
Figure 3.9. (a) Structure of erlotinib. (b)  [1, blue] Most conformationally favorable erlotinib structure 
(compared to the co-crystallized ligand, erlotinib, in PDB ID: 1M172). [2, yellow] Erlotinib conformation 
obtained from PDB ID: 1M17.2 (b) Visualization of 3.11(a) in ATP Site of EGFR. (c) Distances from 

















predicted “hinge region” of EGFR;1b this binding is actually in the “A-loop,” or activation loop 
region, which in terms of this form of EGFR, does not contain the phosphorylated tyrosines that 
are required for EGFR cell signaling; however, this is the usual site for this phosphorylation.1b 
For 3-4a, we hypothesized that the cyano groups of the malononitrile would be important for 
halogen bonding – and this is the case. The cyano group positioned closest to Thr830 (termed 
CN-1, due to its placement closest to the two carbons in the phenyl ring of BMN) is only 3.80 Å 
away, a favorable distance for halogen bonding. This interaction suggests that the cyano 
substituent is necessary for binding. The other cyano moiety has a favorable interaction with 
Phe832, and is in closer proximity (2.65 Å). In terms of the porphyrin, the interactions are less 
favorable. It was hypothesized that the phenyls of TPP should interact heavily with 
phenylalanine or tyrosine residues, that effect was not observed for this conjugate, 3-4a. The 
most favorable interaction appears to be with the 20’-phenyl of TPP; this phenyl group is in 
association with Leu764 that is contained in “Hydrophobic Pocket II” (5.91 Å).  The 
interactions with Phe832 at 15’-phenyl of TPP (7.07 Å) and pi-interactions of the pyrrole 
between phenyls 15’ and 20’ of TPP with Phe699 (6.91 Å) are less favorable. However, the 
region containing Phe699 contains several hydrophobic residues, which may be the driving 
force for the porphyrin to primarily position itself there (Gly695, Ser696, Gly697, Ala698, 
Phe699, Gly700). This region is called the “glycine rich nucleotide-phosphate binding loop,” 
which is located on the N-terminal lobe (N-lobe) of the EGFR sequence.1b Conjugate 3-4a 
docking results are depicted in Figure 3.10 a-d. 
Conjugate 3-6a (Figure 3.11 a) has no favorable interactions at the ATP binding site.  
This BMN has one cyano group and one cyanoacetamide group, rather than two cyano groups 
(conjugate 3-4a). The alkene and phenyl ring of the BMN in conjugate 3-6a have substantial 
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interactions with the porphyrin, resulting in a conformationally constrained porphyrin-
tyrphostin conjugate (Figure 3.11 b, c, d).  Despite the amide inherently pulling electron 
density from the terminal NH2 of conjugate 3-6a, the interaction is favorable enough to 
hydrogen bond with Pro770 (4.87 Å) and the cyano group interacts closest with Leu694 (5.80 
Å). The halogen bonding effect for conjugate 3-6a is insignificant compared to the pi-
interactions of the alkene and phenyl ring with the porphyrin. Porphyrin interactions for this 
conjugate are minimal with other amino acid residues.  The 10’-phenyl of TPP is closest to 
Phe771 (6.70 Å), which is not a favorable hydrogen bonding distance.  The phenyl of the BMN 
interacts favorably with Leu768 (3.55 Å), which is a residue in the “hinge region” of the ATP 



















Figure 3.10.  
(a) Structure of Conjugate 3-4a. (b) Lowest Energy Conformation of Conjugate 3-4a.  
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Figure 3.10. (Continued)  
(c) Visualization of 3-4a (Malononitrile interactions).  



















Figure 3.11.  
(a) Structure of Conjugate 3-6a. 
(b) Lowest Energy Conformation of Conjugate 3-6a. 
















 (a)  
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Figure 3.11. (Continued)  
(c) Visualization of Conjugate 3-6a (BMN interactions). 
(d) Visualization of the Conjugate 3-6a (porphyrin interactions). 
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Malononitrile-terminated porphyrin conjugate 3-7 docking resulted in two low energy 
docked structures (Figure 3.12 b-d), however, unlike the binding of erlotinib (Figure 3.9 a-d) 
at the “Hinge Region” of EGFR, the low energy structures had close interactions with Leu694 at 
CN-1 and Gly772 at CN-2 (as labeled in Figure 3.12 c,d). The first conformer showed 
hydrogen bonding for CN-1 at Leu694 (3.95 Å) and for CN-2 at Gly772 (3.54 Å). The second 
conformer was further away from the Leu694 and Gly772 residues with CN-1 at 5.03 Å and 
CN-2 at 5.42 Å, from Leu694 and Gly772, respectively. The second conformer also had a 
higher energy than the first (16.7 kcal/mol), suggesting this may be an unfavorable 
conformation. Figure 3.12 b show optimized structures of both porphyrin-malononitrile 
terminated conformers. Figures 3.12 c and 3.12 d show the distances for malononitrile 
positions CN-1 and CN-2 at Leu694 and Gly772. For these conformers, we hypothesized that 
hydrogen bonding interactions occur at Thr766 or even Met769, as predicted previously in 
several different binding modes;1a however, this was not the case. The cyano substituents (CN-1 
and CN-2) were closest to the “Solvent Accessible Area” of EGFR, as described in Figure 3.2 
c. The porphyrin’s position for this docking calculation of conjugate 3-7 (Figures 3.12 e, f), 
illustrated that in both conformers, hydrophobic interactions occur at the 10’-position of the 
porphyrin with Gly772, with a minor hydrophobic interaction with C-lobe residue, Ala816, and 
also with “glycine-rich loop” residue, Phe699.   
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 (a)  
 Conformer 1  













Figure 3.12.  
(a) Structure of Conjugate 3-7. 
(b) Lowest Energy Conformations of 3-7 (Conformer 1 - green; Conformer 2 - blue). 
 
 (b)  
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Figure 3.12. (Continued)  
(c) Visualization of 3-7, Conformer 1 (interactions at CN-1 and CN-2). 
(d) Visualization of 3-7, Conformer 1 (porphyrin interactions). 


















Figure 3.12. (Continued) 
(e) Visualization of 3-7, Conformer 2 (Interactions at CN-1 and CN-2). 
(f) Visualization of 3-7, Conformer 2 (Porphyrin Interactions). 
 
 (e)  

















The position of porphyrin-quinazoline conjugate 3-13 (Figure 3.7) was unexpected 
(Figure 3.13 a-c); the entire conjugate spanned part of the N- and C-lobes and the ATP binding 
site. Due to the size of the search space, which was consistent for each experiment, it was 
hypothesized that the bulkier nature of the quinazoline would push the porphyrin into the 
“Solvent Accessible Area” (Figure 3.2), which is near “Hydrophobic Pocket I.” Due to the span 
of conjugate 3-13, the quinazoline actually interacts most favorably with residues in the N-lobe. 
An important (and recognized)1b hydrogen bonding interaction at Asn676 with the 6-position 
oxygen of the OMe substituent (3.90 Å) is evident.  The 7-OMe, on the other hand, is not within 
any favorable length of any residues (>9 Å) and does note protrude into the “Solvent Accessible 
Area.”1b The aniline-H  (4-NH’) hydrogen bonds with Ala674 (4.87 Å) and the N1 of the 
pyrimidine ring interacts favorably with Arg807 (3.94 Å) conjugate 3-13 in the A-loop. The 
porphyrin of conjugate 3-13 is close to the “Hydrophobic Pocket II” (5’-phenyl, Leu764, 6.78 
Å), but spans to interact with Phe771 (15’-phenyl, 7.62 Å). These porphyrin interactions for 
(Figure 3.13 c) are unfavorable because they are too far away. The interaction of the 20’-phenyl 
of TPP with Leu768 at only 2.81 Å, now in “Hydrophobic Pocket I” is favorable, however. 
 (a)  
Figure 3.13. 




Figure 3.13. (Continued) 
 (b) Visualization of 3-13 with Quinazoline (outset). 










The docking result of porphyrin-quinazoline conjugate 3-19 (Figure 3.14) is similar to 
the result obtained with conjugate 3-13. We hypothesized that conjugate 3-19 would have more 
favorable interactions in the “hinge region,” due to its substituents being almost identical to 
erlotinib (Figure 3.9 a). We also hypothesized that the 3-PEG will guide the terminal 
quinazoline (3-19) into the ATP active site, keeping the porphyrin macrocycle outside of the 
binding region.  However, this binding mirrored that of conjugate 3-13; the 6-OMe of 3-13 did 
not interact with Asn676, the N1 of the quinazoline ring did interact with Asn676, however, in 
favorable distance (3.90 Å). The 6-position NH (through which the pegylated porphyrin (2-14) 
is conjugated to the quinazoline ring) shows potential hydrogen bonding with Pro675 at 6.24 Å.  
The aniline-H interacts with Gln677 (3.48 Å), while the 3’-Bromine of aniline ring of 





Figure 3.13. (Continued) 
(e) Visualization of 3-13 (porphyrin interactions). 












Figure 3.14. (a) Lowest Energy Conformer of Conjugate 3-19. (b) Visualization of 3-19 at 
Quinazoline. (c) Visualization of 3-19 (porphyrin interactions). 
 
 (b)   (c)  























































































































































* The third conformer (-5.0 kcal/mol) was used to measure the distance of the atoms from the respective residues, 
as published.1b  + Porphyrin distance for both conformers were similar, <0.5 Å apart.  
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because the design of conjugate 3-19 is similar to that of erlotinib. Porphyrin interactions were 
similar to the observed docking results of conjugate 3-13, but the 20’-phenyl was closer to 
Leu768 (2.58 Å) and a pi-interaction with Phe832 at the 15’-phenyl is important (5.87 Å). 
3.5 Conclusion 
Tyrphostin-based porphyrin conjugates have been synthesized and subjected to 
molecular docking calculations. There are two types of tyrphostin molecules that have been 
synthesized, the BMNs and quinazolines. To synthesize BMNs, Knovenagle condensation was 
conducted in basic conditions, then adding malononitrile or cyanoacetamide (compounds 3-3 
and 3-6). To synthesize the malononitrile-terminated porphyrin conjugate 3-7, carboxylic acid-
terminated porphyrin 2-14 was converted to the aldehyde via a silyl ester intermediate, then 
reduced to the aldehyde, which could then be used in a Knovenagle condensation with 
malononitrile. Conjugate 3-7 was subjected to cellular studies and was found to localize in the 
lysosomes. Two quinazolines were synthesized; one quinazoline was synthesized to allow for 
conjugation of porphyrin 2-14 through the pyrimidine ring (compound 3-12), while the other 
quinazoline was synthesized to allow for conjugation of porphyrin 2-14 through the quinazoline 
phenyl ring (compound 3-18). Computational experiments on tyrphostin-based porphyrin 
conjugates gave insight to the potential binding of these molecules within the EGFR ATP active 
site. The conjugate that was most localized within the EGFR ATP active site was conjugate 3-
6a. We hope to compare these molecules to peptidic-based porphyrin conjugates and assess 
their binding for CRC. Future work includes synthesizing conjugates 3-4a, 3-6a, and 3-19 via 
coupling conditions (HOBt/DIEA/TBTU), purifying by silica gel chromatography as well as 
HPLC, and characterizing them by MS and NMR. The reaction conditions of conjugate 3-7 will 
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be optimized to obtain higher yield of conjugate. These conjugates will be subjected to cellular 
studies to observe their affinity for CRC. 
3.6 Experimental 
Synthesis of 2-(4-nitrobenzylidene)malononitrile (3-2): Malononitrile (0.495 g, 7.5 mmol) 
was dissolved in EtOH in a vial (7.5 mL). At the same time, 4-nitrobenzaldehyde, 3-1 (1.133 g, 
7.5 mmol) was stirred in a 50 mL round bottom flask (RBF) in EtOH (7.5 mL). The 
malononitrile solution was added dropwise to the RBF containing 3-1. After stirring to allow for 
formation of homogeneous solution, piperidine (4.9 mL, 0.05 mmol) was added.  The reaction 
was monitored by TLC.  Afterward, the solution was diluted with 80 mL DCM, washed with 
water (4x), dried with anhydrous NaSO4, and the solvent was removed in vacuo.  The product 
was recrystallized with (hot) EtOH/water and dried by vacuum filtration.  Some insoluble 
product formed was not included with recrystallization.  The mother liquor was stored in a 
refrigerator (~3oC). Crystallized product was stored in an oven (50oC) overnight to yield 49% 
(0.7270 g) of solid yellow crystals. (Literature ppm values correspond to what was obtained 
here.)12, 25 
Synthesis of 2-(4-aminobenzylidene)malononitrile (3-3): Compound 3-2 (0.300 g, 1.5 mmol) 
and anhydrous tin(II) chloride (0.999 g, 105 mmol) were combined in EtOH and stirred.  HCl 
(0.753 mL, 30.56 mmol) was added slowly over 10 minutes.  The entire mixture was stirred 
under reflux for 12 h.  The reaction was monitored by TLC.  Excess EtOH was evaporated.  The 
remaining solution was poured into water and made basic with 15% NaOH solution.  An orange 
precipitate formed that was filtered off, washed with water and recrystallized from EtOH.  The 
orange solid was placed in an oven (50oC) overnight to yield 51% (0.1301 g) of yellow solid. 
(Literature ppm values correspond to what was obtained here.)12, 25 
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Synthesis of Pegylated BMN-Malononitrile (3-4): To a solution of Fmoc-1-amino-4,7,10-
trioxa-13-tridecanamine succinimic acid (noted as “Fmoc-3PEG” in Scheme 3.1a; 0.300 g, 
0.553 mmol) in 0.7 mL DMF, was added DIEA (1.31 mL, 0.619 mmol). The solution was sirred 
for 20 minutes before HOBt (0.084 g, 0.619 mmol) and TBTU (0.199 g, 0.619 mmol) were also 
added to the reaction flask.  The reagents were warmed to 40oC and allowed to activate the 
terminal carboxylic acid of the Fmoc-3PEG for 1h. A solution of 3-3 (0.105 g, 0.619 mmol) in 
0.3 mL DMF was added to the now activated Fmoc-3PEG. The entire solution continued 
stirring under inert atmosphere at 40oC for 48h.  Product was observed by TLC and 
confirmation of crude product was observed by ESI-MS. ESI-MS of C39H43N5O7: m/z Calcd. 
















Figure 3.15 ESI-MS of 3-4. 
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Synthesis of (E)-2-cyano-3-(4-nitrophenyl)acrylamide (3-5): To a RBF was added 3-1 (1.133 
g, 0.010 mol) and 2-cyanoacetamide (0.631 g, 0.010 mol) and stirred/crushed very well to 
ensure homogeneity. Urea (0.450 g, 0.001 mol) was added as a catalyst for the reaction.  This 
mixture was kept at 100oC with constant stirring for 10 minutes. The reaction mixture was 
cooled to room temperature and solidification was observed.  The resulting solid was washed 
with cold water (3x) to remove the urea catalyst, then dried to obtain the product as a yellow 
solid in 70% yield (1.5254 g). 1H-NMR (250 MHz, methanol-d4, ", ppm): 8.41 (2H, d, J=12 
Hz), 8.29 (1H, s), 8.13 (2H, d, J=12 Hz), 8.05 (2H, s).  
Synthesis of (E)-3-(4-aminophenyl)-2-cyanoacrylamide (3-6): Compound 3-5 (0.300 g, 1.381 
mmol) and anhydrous tin (II) chloride (0.916 g, 4.835 mmol) were combined in EtOH and 
stirred.  HCl (0.691 mL, 28.030 mmol) was added slowly over 10 minutes.  The entire mixture 
was stirred under reflux for 12 h.  The reaction was monitored by TLC.  Excess EtOH was 
evaporated.  The remaining solution was poured into water and made basic with 15% NaOH 
solution.  A yellow-orange precipitate formed that was filtered off, washed with water and 
recrystallized from EtOH.  The yellow-orange solid was placed in an oven (50oC) overnight to 
yield 60% (0.1551 g) of yellow solid. 1H-NMR (250 MHz, methanol-d4, ", ppm): 7.88 (1H, s), 
7.71 (2H, d, J=8.7 Hz), 6.63 (2H, d, J=8.7 Hz), 6.39 (2H, s).  
Synthesis of Malononitrile-terminated Pegylated Porphyrin (3-7): Compound 2-14 (0.020 g, 
0.0279 mmol) was treated with 1 equivalent of Et3N (0.00286 g, 0.0279 mmol) and 1.5 
equivalents of bromotrimethylsilyl bromide (0.006414 g, 0.0418 mmol) in dry DCM at 0oC 
under inert atmosphere.  Reaction was completed in 2 hours, as observed by TLC. Reaction 
mixture temperature was brought down to -78oC and left at this temperature for 5 minutes to 
ensure this temperature.  DIBAL-H (0.00397 g, 0.0279 mmol) was added and reaction was 
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monitored every 10 minutes.  Optimum reaction time was 3 minutes. After reaction completion, 
reaction was brought to 0oC and quenched with EtOAc (10 mL).  Celite was added to mixture 
(to remove unreacted metal), then sodium sulfate (to remove residual water).  Reaction mixture 
was warmed to room temperature.  Additional EtOAc was added.  Celite and sodium sulfate 
were filtered. Solvent was removed by vacuum. Reaction was extracted with water (3 x 25 mL), 
organic layers collected, and solvent was evaporated. HRMS-ESI m/z 952.37 [M+H]+, 
calculated for C59H50N8O5 951.08. 1H NMR (400 MHz, CDCl3, ", ppm):  -2.79 (s, 2H), 2.16 
(m, 2H), 3.59-3.60 (m, 10H), 7.26 (s, 1H), 7.61 (t, 1H, J=4.0 Hz), 7.71-7.76 (m, 9H, m-, p-Ph-
H), 8.20-8.30 (m, 8H, 6 o-Ph-H, 2 m-Ar-H), 8.30-8.31 (d, 2H, o-Ar-H, J=5.96 Hz), 8.79-8.8 (s, 
2H, #-H, J=4.8 Hz), 8.84 ((broad), m, 6H, #-H).  
Synthesis of 6,7-dimethoxyquinasolin-4(3H)-one (3-9): 2-amino-4,5-dimethoxybenzoic acid 
(200 mg, 1.014 mmol) and formamidine hydrochloride (136.67 mg, 1.697 mmol) were ground 
together in a small round bottom flask (50 mL) then spread evenly on the bottom of the flask.  
The flask was purged with N2 gas under an air condenser for 30 minutes.  The mixture was then 
heated to 210oC for 15 minutes. Solidification was observed during heating.  After cooling to 
80oC, the mixture was sonicated with 0.33M NaOH. A purple-gray solid was collected on filter 
paper using a water aspirator, then washed an additional 3 times with water.  The residue was 
dried in an oven (70oC) for 8 hrs to obtain 70% yield of purple-grey solid. ESI-MS of 
C10H10N2O3: m/z Calcd. 206.20 [M+H]+, found 207.08. 1H-NMR (250 MHz, DMSO-d7, ", 
ppm): 7.97 (1H, s), 7.43 (1H, s), 7.12 (1H, s), 3.89 (6H, s).  
Synthesis of 4-chloro-6,7-dimethoxyquinazoline (3-10): Oxalyl chloride (559.4 µL, 6.412 
mmol) and 1,2-dichloroethane (2 mL) were stirred in a capped vial for 10 minutes to ensure 
homogeneity under N2 gas at room temperature. DMF (537 µL, 6.412 mmol) was added slowly 
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to the vial. After gas evolution ceased, the vial solution was added to a stirring solution of 3-9 
(0.885 g, 4.275 mmol) in 1,2-dichloroethane (20 mL) and refluxed for 4h.  The reaction was 
allowed to cool to 25oC then quenched with 0.5M Na2HPO4. This mixture was then cooled on 
an ice bath for 3h.  The purple-gray solid was collected using a vacuum filtration, washed with 
water (3x), and left for 1 hour for initial drying.  The residue was dried in an oven (70oC) for 8 
hrs to obtain 97% yield (0.9346 g) of purple-grey solid. ESI-MS of C10H9ClN2O2: m/z Calcd. 
224.64 [M+H]+, found 225.0412. 1H-NMR (250 MHz, DMSO-d7, ", ppm): 9.93 (1H, s), 7.97 
(1H, s), 7.62 (1H, s), 7.16 (1H, s), 4.08 (6H, s).  
 
Synthesis of N1-(tert-butyl)-N2-(6,7-dimethoxyquinazolin-4-yl)ethane-1,2-diamine (3-11): In 
a small RBF, 3-10 (0.0270 g, 0.120 mmol), N-Boc-ethylenediamine (0.0074 mL, 0.117 mmol), 
and K2CO3 (0.016 g, 0.120 mmol) under N2 gas at 60oC.  The mixture was sonicated to ensure 
solubility.  The mixture was stirred for 48h to give desired product. ESI-MS of C16H24N4O2: 
m/z Calcd. 304.39 [M+H]+, found 305.1868. 
 
N1-(6,7-dimethoxyquinazolin-4-yl)ethane-1,2-diamine (3-12): Compound 3-10 (0.099 g, 
0.000445 mol) and K2CO3 (0.100 g, 0.0447 mmol) were stirred vigorously in DMF (30 mL) for 
0.5 h under N2 gas at 60oC. “Reagent Plus”-Ethylenediamine (0.00308 mL, 0.000461 mol) was 
added and a brown solid product formed within 0.5 h, but maximum yield was obtained in 1 h. 
Solvent was evaporated. Product was dissolved in 20% H2O/80% MeOH and filtered through a 
Millipore PTFE Hydrophobic Millex-FG 0.2 µm filter unit. Product was purified by reverse- 
phase HPLC (20% H2O to 50% H2O gradient) on a Waters Atlantis T3 5 mm, 4.6x250mm 
analytical column (C18) to obtain solvent gradient, then was subjected to preparative HPLC 
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using Waters X-BridgeTM BEH300 Prep C18 5 µm, 10x250mm column, to yield 16%-30% of 
product, in 99% purity. Rt = 6.36 minutes. HRMS ESI of C12H16N4O2: m/z Calcd. 248.28 
[M+H]+, found 249.1443.  1H-NMR (400 MHz, DMSO-d7, ", ppm): 8.05 (1H, s), 7.43 (1H, s), 










Figure 3.17. ESI-MS of 3-12. 
  
Figure 3.18. Analytical HPLC Chromatogram for 3-12. 
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Figure 3.19. 1H NMR of Compound 3-12. 
Synthesis of Porphyrin-Conjugate (3-13): Porphyrin 2-14 (0.00431 g, 0.00470 mmol) was 
dissolved in peptide synthesis grade DMF (0.5 mL) under N2. DIEA (40 equiv) was added to the 
mixture and stirred for 1 h. Coupling agents HOBt (0.000634 g, 0.00470 mmol) and TBTU 
(0.00151 g, 0.00470 mmol) were added to the flask. After 1 h of stirring, quinazoline 3-12 
(0.000528 g, 0.00234 mmol) was added. The mixture stirred at 50oCfor 48 h in the dark under 
N2.Purification was conducted by! "ormal-phase chromatography using a gradient (EtAc 
(80%)/DCM (10%)/MeOH (10%), EtAc (70%)/iPrOH (30%), EtAc (60%)/iPrOH (40%), 
EtAc/CHCl3/MeOH (1:1:0.1), EtAc/CHCl3/MeOH/iPrOH (1:1:0.1:0.1), 
EtAc/CHCl3/MeOH/iPrOH (1:1:0.1:0.2)) achieved the product in 16% yield (0.00045 g) of a 
AMQS1C_400.001.esp











































purple solid. ESI-MS of C68H64N10O8: m/z Calcd. 1149.30 [M+H]+, found 1150.3072; [M+K], 
found 1188.3276. 1H-NMR (400 MHz, chloroform-d, ", ppm): 0.07 (s, 2 H) 4.08 - 4.11 (m, 6 H) 
4.11 - 4.16 (m, 18 H) 6.72 - 6.89 (m, 14 H) 7.00 (s, 2 H) 7.06 - 7.21 (m, 13 H) 7.52 (s, 3 H). $ 

























Figure 3.21. 1H NMR of Compound 3-12. 
Synthesis of 7-nitroquinazolin-4(3H)-one (3-15): 2-amino-4-nitrobenzoic acid (200 mg, 1.010 
mmol) and formamidine hydrochloride (357.08 mg, 4.43 mmol) were ground together in a small 
round bottom flask (50 mL) then spread evenly on the bottom of the flask.  The flask was 
purged with N2 gas under an air condenser for 30 minutes.  The mixture was then heated to 
210oC for 15 minutes. Solidification was observed during heating.  After cooling to 80oC, the 
mixture was sonicated with 0.33M NaOH. A bright yellow solid was collected on filter paper 
using a water aspirator, then washed an additional 3 times with water.  The residue was dried in 
an oven (70oC) for 8 hrs to obtain 60% yield of product. Proton NMR was used to confirm 
structure of product. Literature ppm values correspond to the values obtained here.4b, 26 
AMQS-1 (TPP)_F24.001.esp



























































Synthesis of 4-chloro-7-nitroquinazoline (3-16): Oxalyl chloride (559.4 µL, 6.412 mmol) and 
1,2-dichloroethane (2 mL) were stirred in a capped vial for 10 minutes to ensure homogeneity 
under N2 gas at room temperature. DMF (537 µL, 6.412 mmol) was added slowly to the vial. 
After gas evolution ceased, the vial solution was added to a stirring solution of 3-15 (0.885 g, 
4.275 mmol) in 1,2-dichloroethane (20 mL) and refluxed for 4h.  The reaction was allowed to 
cool to 25oC then quenched with 0.5M Na2HPO4. This mixture was then cooled on an ice bath 
for 3h.  The yellow solid was collected using a vacuum filtration, washed with water (3x), and 
left for 1 hour for initial drying.  The residue was dried in an oven (70oC) for 8 hrs to obtain 
50% yield of yellow-orange solid. Proton NMR was used to confirm structure of product. 
Literature ppm values correspond to the values obtained here.4b, 26 
Synthesis of N-(3-bromophenyl)-7-nitroquinazolin-4-amine (3-17): In 20 mL of iPrOH was 
added quinazoline 3-16 (0.050g, 0.239 mmol) and Cs2CO3 (0.155g, 0.477 mmol) for 0.5 h. 4-
bromoaniline (0.0821g, 0.477 mmol) was added to the solution. The mixture was refluxed for 
1h then removed from heat to cool to RT. The solution was concentrated, then water was added 
until the mixture was cloudy. A precipitate formed that was then filtered and dried overnight to 
give 40% of desired product. Proton NMR was used to confirm structure of product. Literature 
ppm values correspond to the values obtained here.4b, 26 
Synthesis of N4-(3-bromophenyl)quinazoline-4,7-diamine (3-18): Compound 3-17 (0.020 g, 
0.578 mmol) and anhydrous tin (II) chloride (0.384 g, 2.020 mmol) were combined in EtOH 
and stirred.  HCl (0.319 g, 8.860  mmol) was added slowly over 10 minutes.  The entire mixture 
was stirred under reflux for 16 h.  The reaction was monitored by TLC.  Excess EtOH was 
evaporated.  The remaining solution was poured into water and made basic with 15% NaOH 
solution.  A light yellow precipitate formed that was filtered off and washed with water (3x).  
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The solid was placed in an oven overnight to yield 42% of product. Proton NMR was used to 
confirm structure of product. Literature ppm values correspond to the values obtained here.4b, 26 
Computational Experimentation: Molecular mechanics calculations at the MM2 level were 
performed using MacroModel and/or Chem Bio 3D running on a Dell Linux Workstation 
equipped with two dual-core Xeon processors or a Gateway Windows Workstation equipped 
with Intel dual-core processor. The geometry of these conformers was optimized and energy 
calculations were performed on the compounds in vacuum.  Molecular docking was performed 
using AutoDock Vina on a Gateway Windows Workstation equipped with Intel dual-core 
processor. The structures of the conjugates were optimized using the aforementioned MM2 
method and the receptor (PDB ID: 1M17) was used as is, with deletion of the bound ligand 
(erlotinib, Figure 3.9 a) via AutoDockTools.23 Output files were prepared using a procedure by 
Trott, et al.21 A test calculation was conducted to confirm accuracy of the “search space.”  
The first calculation contained these parameters: 
Total grid points/map: 15525 
Points in each dimension: x – 24, y – 24, z – 26 
Spacing: 1.000 (angstroms) 
Center grid box: x – 20.0, y - -5.0, z – 50.0 
The second calculation contained:  
Total grid points/map: 16675 
Points in each dimension: x – 28, y – 24, z – 22 
Spacing: 1.000 (angstroms) 
Center grid box: x – 30.0, y - 6.0, z – 60.0  
The second calculation parameters gave the most accurate results for the test calculation of the 
erlotinib ligand in the ATP site of EGFR. Those criteria were used for the additional porphyrin-
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tyrphostin conjugate docking calculations. All porphyrin-tyrphostin conjugates were energy 
minimized (MM2) before docking. Visualization of bound porphyrin-tyrphostin conjugate and 
receptor were conducted in PyMol using residue labels and the “measurement wizard” option in 
PyMol.24 
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CHAPTER 4. SYNTHESIS, CHARACTERIZATION, AND COMPUTATIONAL 
STUDIES OF PORPHYRIN-PEPTIDIC CONJUGATES FOR USE AS IN VIVO 
IMAGING AGENTS FOR COLORECTAL CANCERS (CRC) 
 
4.1 Introduction  
 Previously, in Chapters 1-3, porphyrins and their importance for medicinal applications 
was discussed in great detail.  This Chapter, however, will primarily discuss the conjugation of 
porphyrins to peptides, and to a protein, and investigate their potential as in vivo imaging agents.  
The comparison of non-peptidic porphyrin conjugates, as discussed in Chapter 3, with the 
peptidic conjugates in this Chapter is of great importance – each has specific advantages and 
disadvantages.  In general, peptides and/or proteins tend to undergo proteolytic degradation by 
various proteases in cells, causing them to dissociate, therefore decreasing their efficacy as 
pharmaceutical agents.1  A tyrphostin does not have the same dissociative properties, rather, they 
present a higher structural stability, as they do not have the same labile peptidic bonds.  
However, tyrphostins are much more hydrophobic, therefore potentially increasing the overall 
aggregation of the porphyrin and, tend to show increased toxicity.2  Peptides and proteins, even 
when conjugated to porphyrins, have proven to have high cellular uptake and low dark 
cytotoxicity.3 In consideration of these characteristics of peptides and tyrphostins, the efficacy of 
the synthesized porphyrin conjugates can be compared to find the most favored porphyrin 
conjugate.  
 4.1.1 Prior Synthesis of Porphyrin-Peptide Conjugates 
 The Vicente Laboratory and others have investigated the!synthesis, characterization, and 
medicinal application of porphyrin-peptide conjugates.3b-k, 4 In general, the porphyrin molecules 
contain terminal amino or carboxyl functionalities that are then conjugated to the free N- or C-
terminus of selected peptides.3-5  The process of conjugating the porphyrin to the peptide consists 
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of several steps; the protocols have been optimized to improve yields of the conjugates.  The 
amino- or carboxyl-terminated porphyrin can be conjugated using solution-phase or solid-phase 
conjugation procedures primarily with the following coupling agents in DIEA and DMF: HOBt 
and TBTU.  The porphyrins were first conjugated to water-soluble molecules, such as a PEG, 
then, using the aforementioned coupling agents, the molecule was coupled to the selected 
peptides, such as cell penetrating peptides (CPP), a nuclear localization signal (NLS), or 
bifunctional CPP-NLS or NLS-CPP sequences up to thirty amino acids (Figure 4.1).3  
In regard to cellular uptake, Dr. Vicente’s group found that conjugating a peptide, with an 
affinity for cancer cells, did increase the cell targeting and uptake of the porphyrin-based 
molecule.  In fact, the peptide and PEG groups work concurrently to improve the water-solubility 
of the molecule, thereby decreasing aggregation, and subsequently increasing uptake of these 
conjugates in cells. The PEG also was shown to inhibit steric and electrostatic interactions 
between the peptide and the porphyrin, which would also increase cellular uptake.  We have 
been able to theoretically verify the structure of these conjugates using computational 
chemistry.3c, 3j Dark cytotoxicity was also determined during in vitro studies. Molecules bearing 
the HIV-1 TAT sequence, as referenced in Figure 4.1, were tested against FDA approved 
Photofrin®.3j  This conjugate was less toxic than Photofrin®.3c, 3j These results suggest the 
potential of these conjugates as improved medicinal agents. Intracellular localization of the 
porphyrin-peptide conjugates were analyzed using fluorescence microscopy. The porphyrin-
peptide conjugates localized in several organelles, including the lysosomes3j and the endoplasmic 
reticulum (ER), for example.3 Results indicate that cellular uptake, phototoxicity, and cellular 
localization of porphyrin-peptide conjugates depends on both the structure of the porphyrin (with 
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Figure 4.1. Examples of Previously Synthesized Porphyrin-based 
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or without a PEG linker) and the nature of the peptide sequence.3b-i, 3k 
4.1.2 Conjugation of Porphyrin to Bovine Serum Albumin (BSA) Protein  
The use of proteins as primary medicinal agents has been of great importance in recent 
years.  However, there are many issues with the use of proteins in pharmaceuticals. First, 
proteins are extremely large macromolecules, usually consisting of hundreds of amino acids 
which have varying folding attributes, such as some regions primarily existing as !-sheets, "-
helices, and often, have random coil conformations.6 Because of the differences in potential 
structure, proteins cannot usually be characterized by NMR; proteins are characterized by 
sequencing, circular dichroism (CD) and mass spectrometry (MS), therefore, unless the structure 
has been obtained from protein crystallography, the molecule cannot be fully realized.  
Additionally, there is the issue of potential aggregation, thereby decreasing the medicinal 
efficacy of the protein. As discussed in Chapters 1 and 2, porphyrins are known for their 
aggregation in solution. Other issues affect protein stability, such as temperature, pH, 
concentration, and their solution environments.6 All of these matters may contribute to their 
degradation – an issue that is of extreme importance for their therapeutic relevance.  For this 
project, however, conjugating a protein, such as BSA or EGF, to a porphyrin would provide for a 
method to compare the results of smaller peptidic conjugates to the larger protein conjugates.  
BSA, a protein used frequently in medicinal applications, was used in this project to determine 
the degree of non-covalently bound (NCB) porphyrin in our experiments.4b BSA is a large 
protein consisting of 607 amino acid residues, with a molecular weight of 69,293 Da and varies 
in structure depending on its environment.7 In any case, this protein was an essential piece of 
determining the potential of NCB porphyrin in our conjugates. 
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4.1.3 Types of Peptidic Molecules Utilized in This Project 
The peptidic ligands used in this work, LARLLT8 (6-mer, EGFR L1) and 
(G)YHWYGYTPQNVI9 (13-mer, EGFR L2), were shown to have high affinity for EGFR in 
vitro and in vivo. Two methods were employed to discover these ligands and their affinity for the 
receptor.  The 6-mer was found by using computational chemistry software, AutoDOCK.10 The 
computations in this study focused on one ligand-one enzyme binding.  This was one of the 
ligands with the lowest binding energy suggesting that the ligand is one of the most stable for an 
EGFR “active” site in the receptor’s inactive conformation. In these studies, a different site was 
chosen than the typical EGF binding site. In fact, a site in Domain I of EGFR was chosen, 
consisting of these amino acids: Gln164, Cys163, Ser162, Glu110, Glu073, and Arg074. From 
these results, a library of peptides were designed to be complimentary to these amino acids.11 
Conversely, the 12-mer was found using a “phage display” approach, a technique in which a 
library of peptides were expressed on the outside of a phage virion, and genetic material 
encoding each peptide is contained within the phage. Essentially, a connection between the 
peptide sequence and the DNA is formed.  Then, by using an in vitro selection process called 
panning, each phage, which contains a different peptide sequence, is exposed to a plate 
containing the target of interest and any phage that does not bind is washed away. Because 
computational calculations were not conducted on this peptide, the exact binding region was not 
determined. However, the experiment entailed the competitive inhibition of a high concentration 
of EGF (0.5 mM) using this peptide. Since this 12-mer inhibited binding of EGF, it is clear that 
this peptide most likely binds within the EGFR active site, which contains EGF. Therefore, its 
size, structural characteristics, and electronic behavior are favorable for the EGF site. If EGF can 
be inhibited, then this can also be used for treatment clearly preventing the over-expression of 
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the receptor.  The EGFR L1 and EGFR L2 peptides were exposed to EGFR over-expressing cells 
in vitro and to H1299 xenograft mouse models in vivo.8-9 For each peptide (EGFR L1 and EGFR 
L2) there was high internalization of the peptides and low cytotoxicity.8-9 Therefore, we believe 
that these peptides, when conjugated to porphyrins, will provide with a feasible mechanism in 
the development of in vivo imaging agents. 
4.2 Synthesis of Porphyrin-Peptide Conjugates Using Peptides with Affinity for EGFR 
4.2.1 Synthesis of Peptides, EGFR L1 and EGFR L2 
The peptides mentioned in the previous section, EGFR L1 and EGFR L2, were synthesized 
using Fmoc-solid phase peptide synthesis, or SPPS, at the LSU Protein Facility. While solid 
supports vary, the PAL-PEG-PS resin was used to achieve amide C-terminus, which provides 
stability for the peptide. This resin is used frequently in peptide synthesis. The structure of the 
resin and peptides used are shown in Figure 4.2.  The peptides were cleaved from the resin using 
an acidic “cleavage cocktail” (TFA/liquefied phenol/TIS/H2O) and purified by RP-HPLC using a 
gradient of water and acetonitrile in 1% TFA before conjugation to porphyrins. The relative 
retention times for EGFR L1 and EGFR L2 were 17 minutes and 23 minutes, respectively, which 
is also a measure of hydrophobic character of the peptides.  The column used for purification 
was a Waters XBridgeTM C18 (analytical and preparative). 
 The structures of these peptides vary greatly.  EGFR L1 is shorter in length, yet its make 
up is polar, due to the presence of arginine and threonine residues.  EGFR L1 D1 is in similar 
length, but the peptide is stabilized by the N-methylation on its N-terminus.  N-methylation of 
peptides has proven to decrease the amount of proteolytic degradation in cells.12 While N-methyl 
amino acids are not commonly found in nature, alkylation of the N-terminus increases 
lipophilicity of the peptide, thereby increasing the peptide’s solubility in non-aqueous solvents, 
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but also, similar to porphyrins alone, can improve the permeability of the peptide for the area of 
choice; in this case, cells which greatly over-express EGFR.12 Using an N-methylated peptide 
should help to increase the affinity of the porphyrin-peptide conjugate as well as increase the 
stability of the porphyrin-peptide conjugate. Conversely, EGFR L2 is longer in length, yet is 
more hydrophobic in nature compared to EGFR L1; the presence of larger tyrosine and 
tryptophan residues contribute to this.  EGFR L2 is also bulkier, presenting the issue of potential 
pi-interactions with the porphyrin. EGFR L2, however, contains an additional glycine on its N-
terminus and is therefore not sterically hindered at this position, which is where the carboxylic 
acid-terminated TPP derivative will be conjugated. EGFR L1 does not contain a glycine at its N-
terminus, rather, it contains a lysine side chain. The lysine at the N-terminal end of EGFR L1 as 
well as the N-methylated EGFR L1 indicate these peptides are more sterically hindered at their 
N-terminal ends, where the porphyrin will be conjugated, compared to the N-terminus of EGFR 
L2.  Another difference between EGFR L1 and EGFR L2 are their charges at physiological pH. 
EGFR L1 contains an arginine (pKa ~ 12.5), which an amino acid that is protonated at 
physiological pH.3c  EGFR L2, however, does not contain any charged amino acids and is 
therefore a neutral peptide at physiological pH. The positive charge on the arginine guanidinium 
group is delocalized and can form multiple hydrogen bonds.3c, 3e, 13 Also, the arginine 
guanidinium group is planar and can to bind to negatively charged species (e.g. phosphates).3c, 3e, 
13 It has been reported that arginine-rich peptides have a unique ability to cross cellular 
membranes – an important characteristic for medicinal agents.13 Arginine-rich, cationic 
porphyrin-peptide conjugates (as shown in Figure 4.1) have been observed to have rapid cellular 
uptake, as well as high levels of cellular uptake, compared to other porphyrin-peptide 
conjugates.3c, 3e The high cellular uptake levels of the arginine-rich, cationic porphyrin-peptide 
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conjugate was attributed to the structure of the positively charged guanidinium group, due to its 






















































































(b) EGFR L1 - LARLLT (c) EGFR L1 D1 - N-Methylated LARLLT
(d) EGFR L2 - GYHWYGYTPQNVI
(a) PAL-PEG-PS Resin
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4.2.2 Synthesis of Porphyrin-Peptide Conjugates 
The synthesis of porphyrin-EGFR peptide conjugates was investigated using several different 
methods. As shown in Figure 4.1, the porphyrin-peptide conjugates were synthesised consisted 
of mostly using SPS (Solid Phase Synthesis) with the mono-amino porphyrin, 2-3 or the mono-
carboxylic acid terminated porphyrin 2-5.  After introduction of a spacer and/or a PEG linker, the 
peptides were conjugated by SPS or SNS (SolutioN phase Synthesis) to the porphyrin.  The the 
best method for conjugating the peptides to 2-5 or 2-7 was observed to SNS.  Additionally, the 
coupling conditions varied for these conjugates.  Previously, it was reported that the solid phase 
conjugations took place in HOBt and TBTU, but in this case, the solution phase conjugations 
gave low yields using these agents, and rather, HOBt and HBTU were used to achieve optimal 
results.  In fact, several coupling agents and reaction conditions were investigated.  Table 4.1 
illustrates the different types of coupling conditions used for this experimentation. The best 
reagent conditions are highlighted in gray. The Scheme for the synthesis of these molecules is 
shown in Scheme 4.1. 
As stated above, the coupling agents varied.  Various coupling agents were used in an 
attempt to optimize yields. These reagents are: HOBt/TBTU, HOBt/HBTU, and PyAOP. The 
structures of these coupling agents are shown in Figure 4.3.  The structures of each coupling 
agent are very similar.  HOBt is added to coupling conditions to prevent racemization.14  The 
benzotriazole ester intermediate (-OBt) is less reactive than the O-acylisourea, therefore 
preventing additional side reactions.14  Usually, a “preactivation” step is used to prepare the 
carboxylic acid for coupling the N-terminal end of an amino acid.14a The base, DIEA, was added 
to the carboxylic acid porphyrin (2-4, 2-7, or 2-14) and allowed to react for several minutes (10 
minutes – 1.0 h), after which HOBt and TBTU/HBTU were added to the reaction mixture.  The 
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amine terminated spacer, PEG, and/or peptide were added, and the reaction continued, usually 
for at least 48 h. TBTU was developed first as an improvement upon traditional EDCI and DCC 
couplings, and it was proven to be a stronger coupling agent.14  HBTU, a close derivative, also 
illustrates high coupling yields, upwards of 95% in many cases.14a  HBTU, however, produces 
toxic by-products.15 Previous work states that the counterions of TBTU and HBTU, BF4- and 
PF6-, respectively, do not have any effect on the high coupling rate or the decrease in 
racemization in peptide couplings.16 PyAOP, conversely, is a coupling reagent of the 
“phosphonium” family, proven to be an even stronger coupling agent than TBTU or HBTU.14a  
In fact, PyAOP is more typically effective than any OBt analog, and can be used alone, without 
any additives.14a The differences in yields of peptide porphyrin conjugates, 4-5, 4-6, 4-7, 4-8, 4-


































Table 4.1 Synthesis Attempts for This Series of Porphyrin-Peptide Conjugates. 







EGFR L1 NL 
(4-5) 
SPS HOBt/TBTU DMF 6 equiv DIEA, 48-72 h, RT <1% 
SNS HOBt/HBTU DMF 6 equiv DIEA, 48 h, RT 19%-21% 
EGFR L1 3 
PEG (4-7) 
SPS HOBt/TBTU DMF 6 equiv DIEA, 72 h, RT <1% 
SNS HOBt/HBTU DMF 6 equiv DIEA, 36 h, RT 34% 
EGFR L1 D1 
3PEG (4-8) 
SNS HOBT/TBTU DMF 6 equiv, DIEA, 48 h -72 h, RT <1% 
SNS HOBt/HBTU DMF 6 equiv DIEA, 36 h, RT 5% 
EGFR L2 NL 
(4-6) SPS HOBt/TBTU DMF 
10 equiv DIEA, 5 
d, RT 59% 
EGFR L2 
3PEG (4-9) 
SPS HOBt/TBTU DMF 6 equiv DIEA, 36 h, RT <1% 
SNS HOBt/TBTU DMF 6 equiv DIEA, 36 h, RT <1% 
SNS HOBt/TBTU DCM 6 equiv DIEA, 36 h, RT <5% 
SNS HOBt/HBTU DMF 10 equiv DIEA, 48 h, RT 10%-40% 




SPS HOBt/TBTU DMF 6 equiv DIEA, 48 h, RT 10% 


















1. HOBt/TBTU, DIEA, DMF











4-10: R = EGFR L2
4-10
Scheme 4.1. (Continued) 
(b) Synthesis of Porphyrin-Peptide Conjugate 4-10. 




























  DIEA, DMF
    2. NH2-3PEG-tBu 





















1. HOBt/TBTU, DIEA, DMF
2. Peptidyl Resin (R)
RT, 72 h
(59%)
4-5: R = LARLLT (EGFR L1)
4-6: R = GYHWYGYTPQNVI (EGFR L2) 2-14: R = OH 4-7: R = EGFR L1
4-8: R = EGFR L1 D1
4-9: R = EGFR L2
Method A:










































4.2.3 Preliminary Cell Studies for Porphyrin-Peptide Conjugates 
To investigate the biological properties of our conjugates, we subjected several 
conjugates to cell assays for cytotoxicity and uptake. Porphyrin-peptide conjugates 4-5, 4-7, and 
4-9 were subjected to HEp2 cells (a human epidermoid carcinoma, and larynx cancer cell line) to 
observe cellular uptake levels.17 These results are shown in Figure 4.4. The cellular uptake data 
shows that each porphyrin-peptide conjugate 4-5, 4-7, and 4-9 are taken into HEp2 cells more 
than porphyrin 2-14, which was used as a control.  Conjugate 4-7, however, has the highest 
cellular uptake.  This conjugate contains the EGFR L1 peptide, which has an arginine residue.  
This result is in agreement with literature data; the positively charged peptide is rapidly taken 
into cells in comparison to peptides that do not contain an arginine.3c, 3e, 13a, b Similarly, conjugate 
4-5 also contains the EGFR L1 peptide and has higher levels of cellular uptake than the 
conjugate 4-9, which has EGFR L2. EGFR L2 is neutral at physiological pH and is expected to 
have lower cellular uptake values in comparison to EGFR L1. Conjugate 4-7 contains a PEG 
linker, which has been shown in previous investigations to increase cellular uptake of porphyrin-
peptide conjugates.3j, k These results suggest that the nature of the EGFR L1 peptide, in particular 
the protonated arginine in the peptide sequence, as well as the presence of a PEG linker, are 
important for cellular uptake.  
Phototoxicity studies were carried out in human HEp2 cells with compounds 2-14, 4-5, 
and 4-7. Porphyrin conjugates can show high phototoxicity after activation of the porphyrin 
macrocycle with light due to the production of singlet oxygen and other cytotoxic species that 
destroy tumor cells.3b, 18 For in vivo imaging, increased phototoxicity levels will decrease the 
effectiveness of this technique.19 Figure 4.5 shows the results of phototoxicity of 2-14, 4-5, and 
4-7 in human HEp2 cells using 1 J/cm2 light dose. Conjugate 4-7, was illustrated in this work to  
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have the highest phototoxicity levels compared to conjugate 4-5 and the control, porphyrin 2-14. 
Conjugate 4-7 contains the PEG linker with EGFR L1 peptide, while conjugate 4-5 contains the 
EGFR L1 peptide, but does not contain a PEG. Conjugate 4-5, therefore, may be effective as an 
in vivo imaging agent due to its increased cellular uptake and low phototoxicity levels. 
 In another preliminary cellular study, porphyrin-peptide conjugates 4-5, 4-7, and 4-9 
were taken up by COS7 cells, a kidney cell line from the African green monkey species that does 
not over-express EGFR,20 and A431 cells, a human carcinoma cell line that greatly over-
expresses EGFR on its cell surface; the receptor is found at 3x106 per cell21 and makes up 
approximately 0.2% of the carcinoma proteins.21-22!The results of this study, obtained by Dr. 
Inder Sehgal, are shown in Table 4.2. There is evidence that the conjugate that is most preferred 
  
 
Figure 4.4. Uptake of Porphyrin 2-14 and Porphyrin-Peptide Conjugates 4-5, 4-7, and 




for the A431 cells, or the conjugate with the most affinity for EGFR, is conjugate 4-9, which has 
the EGFR L2 peptide.  The primary goal of these syntheses is to develop a porphyrin-peptide 
conjugate that has an affinity for EGFR, and this data suggests that the porphyrin-peptide 
conjugate that has a higher affinity for EGFR is 4-9. This is a promising result for our studies, 
although the fluorescence values seemed lower than anticipated. While the porphyrin-peptide 
conjugates 4-5, 4-7, and 4-9 have higher fluorescence levels in the COS7 cell line, the EGFR L2-
based porphyrin conjugate 4-9 maintains a high fluorescence intensity in both the COS7 cells 
and in A431 cells.  
Figure 4.5. Phototoxicity of Porphyrin 2-14, Conjugate 4-5, and Conjugate 4-7 in 
Human HEp2 Cells Using a Cell Titer Blue Assay and a Light Dose of 1 J/cm2. 
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4.3. Synthesis of Porphyrin-BSA Conjugate 
 To further assess the activity of the porphyrin-peptide conjugates, we wanted to compare 
the activity of these molecules with a porphyrin-EGF conjugate.  As a model study, further 
conjugation of the porphyrin with a protein, BSA, was used.  EGF is more expensive and this 
study served as a preliminary investigation. In order to determine the amount of NCB porphyrin 
in a conjugation reaction with a protein, the pegylated porphyrin 2-14 was conjugated to BSA 
protein.  The amount of NCB porphyrin is impotrant to consider because the presence of NCB 
porphyrin may decrease selectivity for porphyrin conjugates.4 This is of great importance 
because we desire a highly specific porphyrin-peptide conjugate.  The conjugation was carried 
out by dissolving porphyrin 2-14 in DMF, then adding NHS and DCC to the reaction mixture.  
This coupling reaction facilitates the formation of the NHS ester, which adds to the terminal 
carboxylic acid of porphyrin 2-14.  The reaction took place at room temperature for 12 h under 
nitrogen. The reaction was monitored by TLC to ensure formation of the terminal NHS ester.  
BSA protein was added to the reaction mixture and the conjugation of BSA to pegylated 
porphyrin 2-14 was completed in 16 h.  The porphyrin-protein conjugate was purified using a G-
a - Net mean [and standard deviation] of pixel intensities taken 
from a histogram of the bitmap image of cells.  Cells were 
imaged for 2 seconds at 200x through a Texas Red filter set with 
emission detection between 607 and 682 nm.  
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25 column, yielding enough porphyrin-protein conjugate 4-11 to prepare a 3.0 mg mL-1 solution 
for gel electrophoresis. (The concentration is approximately 3.0 mg mL-1, which is standard, 
according to the literature.4b)  A description of the process of conjugation is noted in Figure 4.6.   
The evidence of the product was observed by gel electrophoresis, which is illustrated by the 
molecular weight at approximately 40kD.  At the higher concentration, 3.0 mg mL-1 (Figure 4.6 
a), NCB porphyrin is evident; there several bands below 10kD that illustrate the presence of 
porphyrin that did not bind to BSA.  However, at half of the initial concentration (1.5 mg mL-1, 
Figure 4.6 b) the band of NCB porphyrin is not detected by the naked eye. This result is 
important because porphyrins can be given to a patient at high concentrations, however, this 
proves that if some of the porphyrin is ineffective or unspecific for the treatment, there is a loss 
of efficacy for the agent.  These results illustrate that NCB porphyrin could be an issue with 
lowered specificity of our porphyrin-peptide conjugates.! In order to avoid NCB porphyrin, 
processes, such as gel electrophoresis, must be implemented to remove the porphyrin.  Future 
studies will include quantifying the amount of NCB porphyrin observed by exising the NCB 
porphyrin band from the gel and using an acetone precipitation method.4b 














DMF, RT, 12 h
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4.4. Selected Computational Studies of Porphyrin-Peptide Conjugates 
 Chapter 3 described several computational studies that would be relevant for this project.  
This includes molecular mechanics and molecular docking studies on our porphyrin conjugates 
using force fields to minimize energies/geometries and subsequently using a docking program to 
observe potential binding of the conjugates.  The same was done for the porphyrin-peptide 
conjugates 4-5, 4-6, 4-7, and 4-9, for this project.   
Figure 4.6. Gel Electrophoresis of Porphyrin-BSA Protein Conjugates. 
Lanes  
(a) 3.0 mg/mL Concentration 
(1) BIO-RAD KaleidoscopeTM marker, (2) Pure BSA, (3) – (5) Porphyrin-BSA Conjugate, 
(6) BIO-RAD Precision Plus ProteinTM marker, (7) Porphyrin-BSA Conjugate, (8) – (9) 
Pure BSA. 
(b) 1.5 mg/mL Concentration 
(1) BIO-RAD KaleidoscopeTM marker, (2) Pure BSA, (3) – (5) Porphyrin-BSA Conjugate, 






 4.4.1 MM2 Force Field Application for Porphyrin-Peptide Conjugates 
 Instead of using ab initio calculations for these porphyrin-peptide conjugates, energy and 
geometries were minimized using the MM2 method (in vacuum), which is typically used for 
large organic molecules.23 With this data, we observed important aspects about our porphyrin-
peptide conjugates.  It is obvious from Figure 4.7 that the conjugates that do not contain a PEG 
have substantial electrostatic interactions with the porphyrin ring.  This was previously 
confirmed in our group; the lack of PEG may hinder the peptide from solely arriving at the active 
site of EGFR.3g, 3j Conversely, when the PEG was included in the computational studies, the 
peptide is positioned away from the porphyrin, even in the case of EGFR L2, the peptide which 
contains several hydrophobic, aromatic residues that may favor potential pi-interactions with the 
porphyrin.  It is evident, then, that having a PEG is geometrically favorable for these conjugates. 
4.4.2 AutoDOCK4 for Porphyrin-Peptide Conjugates 
 In Chapters 1 and 3, a thorough discussion of docking software, AutoDOCK and 
AutoDOCK Vina were described.  The importance of using these applications is to observe 
potential binding of a ligand within the active site of the molecule of interest.  With the 
assistance of our collaborator, Dr. S. Jois at the University of Louisiana-Monroe, selected 
conjugates were docked in AutoDOCK 4 using an active conformation of EGFR (PDB ID: 
1M17).  The docked conjugates 4-6 and 4-7 are shown in Figures 4.9 and 4.10. In each figure, 
the porphyrin is outside of the active site, therefore suggesting that the porphyrin should not 
interfere with the binding of the peptide to the receptor.  This potential binding illustration is also 
confirmed by the MM2 minimized geometry of conjugate 4-6 (Figure 4.7); although the overall 
conjugate is more constrained, EGFR L2 still positions itself away from the porphyrin.  Figure 
4.8, on the other hand, confirms the importance of the PEG for these conjugates. As observed in 
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Figure 4.8, EGFR L1 positions itself away from the porphyrin as well.  This is in great 
comparison to the MM2 optimized geometry in Figure 4.7; the EGFR L1 porphyrin conjugate 
without a PEG is highly constrained, and therefore, may not bind as efficiently as EGFR L2 
without a PEG linker.  












R = LARLLT (EGFR L1)



















R = LARLLT (EGFR L1)
R = GYHWYGYTPQNVI (EGFR L2)
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Lowest Energy Conjugate 
(Light Pink) 
Pictured: Eight (8) low energy docked 
structures in EGF binding site on EGFR. 
Figure 4.9 











R = GYHWYGYTPQNVI (EGFR L2)
Pictured: Three (3) low energy docked 
structures at EGF binding site on EGFR. 

















R = LARLLT (EGFR L1)
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4.5 Conclusion 
Porphyrin-peptide conjugates 4-5, 4-6, 4-7, 4-8, and 4-9 aim to improve the selective 
delivery of fluorescent porphyrin molecules into CRC cells. The approach involves conjugation 
of peptidic biomolecules, via a small peptide ligand to a porphyrin through a short glycine spacer 
and/or a PEG linker. The two peptides used for conjugation were EGFR L1 and EGFR L2, which 
differ in length of amino acids, hydrophobic character, and overall charge at physiological pH 
(Figure 4.2). The method of conjugation of porphyrins 2-7 or 2-14 to EGFR L1, EGFR L1 D1, 
or EGFR L2, gave the highest yields with SPS (Scheme 4.1).  Preliminary cell studies illustrate 
that in HEp2 cells, Conjugates bearing the EGFR L1 peptide have increased cellular uptake 
compared to conjugate 4-9, which bears EGFR L2 (Figure 4.4). Additionally, conjugate 4-7 has 
the highest cellular uptake, which may be due to the effect of the PEG linker and the cationic 
peptide EGFR L1.  Conversely, conjugate 4-7 has the highest phototoxicity levels in comparison 
to conjugate 4-5 (Figure 4.4). The porphyrin-peptide conjugates designed in this study should 
have lower phototoxicity levels for in vivo imaging application of CRC. This data suggests that 
conjugate 4-7, due to its increased cellular uptake and low phototoxicity, has promising 
characteristics for use as an in vivo imaging agent (Figure 4.5).  However, the porphyrin-peptide 
conjugates should also have a specific affinity for cells that over-express EGFR, like CRC.  
Therefore, a study was carried out to assess the potential of conjugates 4-5, 4-7, and 4-9 to have 
more affinity for A431 human carcinoma cells.  In this study, conjugate 4-9 had the most affinity 
for the A431 cells, evidenced by data in Table 4.2 and Figure 4.5.  A porphyrin-BSA conjugate 
was also synthesized to assess the amount of NCB porphyrin as a preliminary study.   
Future work includes synthesizing a porphyrin-EGF conjugate to compare the effect of 
this conjugate (through cellular uptake, phototoxicity, dark toxicity, and affinity for EGFR) to 
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porphyrin-peptide ligands.  Lastly, porphyrin-peptide conjugates were subjected to 
computational studies to assess their lowest energy conformations in the EGF binding site of 
EGFR.  These computational results suggest that porphyrin-peptide conjugates may bind at the 
EGF binding site.   In future work, yields of porphyrin-peptide conjugates will be optimized by 
using the best conditions for conjugation. Conjugates will be purified by HPLC and 
characterized by MS, UV-VIS, fluorescence, and NMR. Additionally, cell studies will be 
conducted on all porphyrin-peptide conjugates again and subcellular localization of the 
conjugates will be observed by fluorescence microscopy.  
 
4.6 Experimental 
Synthesis of Conjugate EGFR L1 NL (4-5): To a peptide synthesis vial was added porphyrin 
2-7 (0.006 g, 0.00839 mmol) in peptide synthesis grade DMF (0.05 mL) and DIEA (6-10 equiv) 
under inert atmosphere.  The carboxylic acid was allowed to activate for 1 h at RT before adding 
the coupling agents, HOBt (0.00133 g, 0.00839 mmol) and HBTU (0.00318 g, 0.00839 mmol). 
The mixture stirred for an additional hour before adding purified EGFR L1 (0.0115 g, 0.0168 
mmol). After 48 h, the crude conjugate was analyzed for its molecular weight by MALDI-MS. 
The mixture was dried down under vacuum, filtered with a Millipore PTFE Hydrophobic Millex-
FG 0.2 µm filter unit, and subjected to RP-HPLC on a Waters XBridgeTM C18 column 
(analytical and preparative) and using a water/acetonitrile gradient in 0.01% TFA (35% 
H2O/65% ACN, 10% H2O/90% ACN, 35% H2O/65% ACN).  The product was obtained in 21% 
yield (95% purity). Rt = 5.06 minutes.  MALDI-MS m/z 1325.789 [M-59]+ (Arginine related 
ion), 1383.793 [M+H]+, calculated for C78H91N15O9 1382.65. 
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!Figure 4.11. HRMS ESI of Conjugate 4-5. 
 
Figure 4.12. Analytical HPLC Chromatogram of Conjugate 4-5. 
Synthesis of Conjugate EGFR L2 NL (4-6): To a peptide synthesis vial was added porphyrin 
2-7 (0.0930g, 0.00954 mmol) and DIEA (6 equiv) in 0.7 mL of peptide synthesis grade DMF. 
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This mixture was stirred for 1 h before HOBt (0.00129 g, 0.00954 mmol) and TBTU (0.00306 g, 
0.00954 mmol) were added to the vial and continued to stir for an additional hour. 
Simultaneously, resin bound EGFR L2 (0.00760 g, 0.00477 mmol) was added to a peptide 
synthesizer and swelled for 1 h in peptide synthesis grade DMF (1.5 mL). The activated 
porphyrin and coupling agents were then transferred to the peptide synthesizer, purged with N2, 
then capped tightly. The peptide synthesizer was then attached to the mechanical rotater and the 
reaction continued for 48 h at RT. After reaction completion, excess unreacted porphyrin and 
coupling agents were washed away using DMF, MeOH, and DCM until the supernatant was 
colorless.  After drying under vacuum aspirator for 0.5 h, the resin was subjected to a “cleavage 
cocktail” consisting of 1 mL of TFA (88%), liquefied phenol (5%), triisopropylsilane (2%), and 
water (5%) was added to the resin beads for 4 h.  The resin was filtered and washed with TFA (3 
x 1 mL).  The green filtrates were combined, evaporated, and washed with cold anhydrous ether 
until precipitation occurred. The precipitates were washed again with cold anhydrous ether and 
dried under vacuum (or lyophilized in 50% H2O/50% ACN). A pre-filtration step was conducted 
using a filtered with a Millipore PTFE Hydrophobic Millex-FG 0.2 µm filter unit. Purification 
was conducted by RP-HPLC using a water/acetonitrile gradient in 0.01% TFA (10% H2O/90% 
ACN, 90% H2O/10% ACN, 10% H2O/90% ACN) on a Waters XBridgeTM C18 Column to yield 
59% of conjugate (89% purity). Rt = 30.13 minutes. MALDI-TOF-TOF m/z 1599.082 [M-
C94H83N15O11] (Porphyrin and peptide to amino acid residue #7 (tryptophan)), 1618.902 [(M-




Figure 4.13. MALDI-TOF-TOF of Conjugate 4-6.
 
Figure 4.14. High Resolution MALDI of Conjugate 4-6. 
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Figure 4.15. Analytical HPLC Chromatogram of Conjugate 4-6. 
Synthesis of Conjugate EGFR L1 3-PEG (4-7): To a peptide synthesis vial was added 
porphyrin 2-14 (0.002 g, 0.00218 mmol) in peptide synthesis grade DMF (0.03 mL) and DIEA 
(6-10 equiv) under inert atmosphere.  The carboxylic acid was allowed to activate for 1 h at RT 
before adding the coupling agents, HOBt (0.000588 g, 0. 00218 mmol) and HBTU (0.00165 g, 
0.00218 mmol). The mixture stirred for an additional hour before adding purified EGFR L1 
(0.00298 g, 0.00435 mmol). After 48 h, the crude conjugate was analyzed for its molecular 
weight by MALDI-MS. The mixture was dried down under vacuum, filtered with a Millipore 
PTFE Hydrophobic Millex-FG 0.2 µm filter unit, and subjected to RP-HPLC on a Waters 
DeltaPak C18 column (analytical) using a water/acetonitrile gradient in 0.01% TFA (10% 
H2O/90% ACN, 90% H2O/10% ACN, 10% H2O/90% ACN).  The product was obtained in 31% 
yield (95% purity). Rt = 22.24 minutes.  MALDI-MS m/z 1325.789 [M-59]+ (Arginine related 




















































Figure 4.16. MALDI-TOF of Conjugate 4-7. 
 





Figure 4.18. Analytical HPLC Chromatogram Conjugate 4-7. 
Synthesis of Conjugate N-Methylated EGFR L1 D1 3-PEG (4-8): To a peptide synthesis vial 
was added porphyrin 2-14 (0.002 g, 0.00218 mmol) in peptide synthesis grade DMF (0.03 mL) 
and DIEA (6-10 equiv) under inert atmosphere.  The carboxylic acid was allowed to activate for 
1 h at RT before adding the coupling agents, HOBt (0.000588 g, 0. 00218 mmol) and HBTU 
(0.00165 g, 0.00218 mmol). The mixture stirred for an additional hour before adding purified N-
methylated EGFR L1 D1 (0.00305 g, 0.00435 mmol). After 48 h, the crude conjugate was 
analyzed for its molecular weight by MALDI-MS. The mixture was dried down under vacuum, 
filtered with a Millipore PTFE Hydrophobic Millex-FG 0.2 mm filter unit, and subjected to RP-
HPLC on a Waters Delta Pak C18 or a Waters XBridgeTM C18 (analytical) column using a 





































H2O/90% ACN).  The product was obtained in 4.4% yield. Rt = 48.0 minutes.  MALDI-MS m/z 
568.199 [M+3H]+, 1680.991 [M+2K]+, 1736.911 [M+HOBt] calculated for C88H110N16O13 
1599.91.  
 
Figure 4.19. MALDI-TOF-TOF of Conjugate 4-8. 
 
 
Figure 4.20. MALDI-TOF-TOF of Conjugate 4-8. 
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Synthesis of Conjugate EGFR L2 3-PEG (4-9): To a peptide synthesis vial was added 
porphyrin 2-14 (0.002 g, 0.00109 mmol) in peptide synthesis grade DMF (0.03 mL) and DIEA 
(6-10 equiv) under inert atmosphere.  The carboxylic acid was allowed to activate for 1 h at RT 
before adding the coupling agents, HOBt (0.000588 g, 0. 00109 mmol) and HBTU (0.00165 g, 
0.00109 mmol). The mixture stirred for an additional hour before adding purified EGFR L2 
(0.00174 g, 0.00218 mmol). After 48 h, the crude conjugate was analyzed for its molecular 
weight by MALDI-MS. The mixture was dried down under vacuum, filtered with a Millipore 
PTFE Hydrophobic Millex-FG 0.2 mm filter unit, and subjected to RP-HPLC on a Waters 
DeltaPak C18 column or Waters XBridgeTM C18 (analytical) using a water/acetonitrile gradient 
in 0.01% TFA (10% H2O/90% ACN, 90% H2O/10% ACN, 10% H2O/90% ACN).  The product 
was obtained in 10%-40% yields (98% purity). Rt = 19.30 minutes (Purity is for normalized 
data).  MALDI-MS m/z 1138.550 [M-C67H63N9O9]+, 1161.534 [(M-C67H63N9O9)+Na]+, 
2612.278 [M+5Na]+, 2499.183 [M+H]+, calculated for C133H150N25O25 2498.76.!!
 




Figure 4.21. MALDI-TOF-TOF (b)of Conjugate 4-9. 
 




Figure 4.23. Analytical HPLC Chromatogram of Conjugate 4-9. 
Synthesis of Conjugate EGFR L2 NL with Diglycolic Anhydride Porphyrin 2-4 (4-10): To a 
peptide synthesis vial was added porphyrin 2-4 (0.010g, 0.0134 mmol) and DIEA (6 equiv) in 
0.7 mL of peptide synthesis grade DMF. This mixture was stirred for 1 h before HOBt (0.00725 
g, 0. 0134 mmol) and TBTU (0.00430 g, 0. 0134 mmol) were added to the vial and continued to 
stir for an additional hour. Simultaneously, resin bound EGFR L2 (0.00107 g, 0.00670 mmol) 
was added to a peptide synthesizer and swelled for 1 h in peptide synthesis grade DMF (1.5 mL). 
The activated porphyrin and coupling agents were then transferred to the peptide synthesizer, 
purged with N2, then capped tightly. The peptide synthesizer was then attached to the mechanical 
rotater and the reaction continued for 48 h at RT. After reaction completion, excess unreacted 
porphyrin and coupling agents were washed away using DMF, MeOH, and DCM until the 
supernatant was colorless.  After drying under vacuum aspirator for 0.5 h, the resin was 
subjected to a “cleavage cocktail” consisting of 1 mL of TFA (88%), liquefied phenol (5%), 
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triisopropylsilane (2%), and water (5%) was added to the resin beads for 4 h.  The resin was 
filtered and washed with TFA (3 x 1 mL).  The green filtrates were combined, evaporated, and 
washed with cold anhydrous ether until precipitation occurred. The precipitates were washed 
again with cold anhydrous ether and dried under vacuum (or lyophilized in 50% H2O/50% 
ACN). MALDI-TOF-TOF m/z 1733.833 [M-C99H92N16O14] (Porphyrin and peptide to amino 
acid residue #8 (threonine)), 1657.727 [(M-C96H85N15O13]. 2333.568 [M+K]+, 2295.057 [M+H]+, 
calculated for C125H133N23O22 2309.52. 
 
Figure 4.24. MALDI-TOF-TOF of Conjugate 4-10. 
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CHAPTER 5. BODIPY PEPTIDOMIMETIC CONJUGATES TARGETED TOWARD 
HER-2 AS THERAPEUTIC AGENTS FOR BREAST CANCER 
5.1 The Importance and Versatility of BODIPYs 
As illustrated in Chapter 1, much work has been conducted on the development of novel 
BODIPYs (Figure 5.1), due to their usefulness in science and medicine.1 While derivatives of 
“porphyrin’s little sister”2 were first synthesized in 1968,3 interest in this field has greatly 
increased since the 1990s.1a This is mostly an effect of the realization for BODIPYs to be used in 
cellular imaging techniques.1a In order for a molecule to be considered as useful for medical 
imaging or treatment, there are several criteria that the molecule must meet, primarily its low 
toxicity to normal tissues.  Like porphyrins, BODIPYs are highly fluorescent, and depending on 
the substitution on the BODIPY core, can emit wavelengths into the visible and near-IR (NIR) 
range.  This is one of the main reasons these molecules can be used as fluorescent labels that are 
attached to proteins,1 antibodies,1 DNA,1 or oligosaccharides.4   
 
The primary aspects of BODIPYs that secure their attractiveness as fluorescent imaging 
agents are the following: they are stable in different environments (acidic, basic, various 
temperatures),1, 5 tend to have a lower degree of aggregation compared with porphyrin 
derivatives,4 have high fluorescence quantum yields,1-2, 4-5 possess high molar extinction 
coefficients, and have inconsequential triplet state formation (a quality of importance when 
discussing their fluorescence capabilities),1-2, 5 are soluble in a variety of solvents (including 




















water, depending on the degree of water-soluble moieties on the BODIPY scaffold),1-2, 4-5 and 
can emit at wavelengths greater than 500 nm.1-2, 5 
It is also important to consider the major disadvantage of using BODIPYs, as well as 
other organic dyes, in general for imaging applications.  One of the most prominent issues is that 
the Stokes’ shift in organic dyes tends to be small (less than 15 nm).5b, 6 A small Stokes’ shift is 
an indication that the molecule has a tendency for self-absorption, thus decreasing emission 
wavelength intensity, one of potential causes of an “inner filter effect.”6-7 This is a crucial 
consideration because the techniques and applications for which BODIPY dyes are used, such as 
biological imaging4, 6 or as molecular probes,6 require large Stokes’ shifts to avoid the issue of 
lower fluorescence emission intensities.6 Most recently, BODIPY dyes have been developed 
with Stokes’ shift values of approximately 96 nm.6 For molecules with very small Stokes’ shifts, 
however, additional considerations are taken when conducting fluorescence measurements. 
There is a need for narrowband filters to be incorporated into the fluorescence instrumentation, 
or, a highly selective excitation source must be used, both of which are expensive to incorporate 
into fluorescence measurements.5b, 8  It is usually proposed that in order to modify the Stokes’ 
shifts, that two chromophores be incorporated into one molecule, with one being an energy donor 
(high energy absorbing chromophore) and the other being an energy acceptor (lower energy 
emitting chromophore).5b In another approach, Ziessel and colleagues modified the fluorines in 
F-Bodipy with anthracene and pyrene. The largest Stokes’ shift attained, using this methodology, 
was 54 nm (Figure 5.2 A).5b In most recent work, Chen & colleagues modified the BODIPY 
core at the meso-, 2-, and 6- positions with phenyl, and thiophene substituents, respectively 




It is important to note that the fluorescence quantum yields for the compounds illustrated in 
Figure 5.2 were 25% (in DCM)5b and 20.6% (in PhCH3)6, for 5.2 (A) and 5.2 (B), respectively. 
While other compounds listed in these publications had Stokes’ shifts smaller than 50 nm, 
several of the quantum yields reached 85%-90%.5b, 6 Also, while the Stokes’ shifts improved, the 
applications in which these molecules may be used will require the addition of water-soluble 
substituents, which may alter the Stokes’ shift.  
5.2 BODIPY Syntheses 
 With the increase of BODIPY-related papers being published, that the synthesis of the 
BODIPY core follows three general methods: 1. Condensation from pyrrole and aldehyde, 2. 
Condensation via pyrroles and acid chlorides (or anhydrides), 3. Condensation from 
ketopyrroles.1 Other BODIPY derivatives consist of the addition of heteroatom substituents (as 
illustrated in Figure 5.2 (B)), substitution of the fluoride atoms with various groups bonded to 
the boron (illustrated in Figure 5.2 (A)), extended conjugation of the BODIPY core or through 
vinyllic substitution at the 3- and/or 5-positions of the BODIPY, among others.1 These three 
methods mentioned above provide routes to synthetically useful BODIPY molecules for use in 










Figure 5.2. Selected BODIPY Structures with Stokes’ Shifts >50 nm  
(A) Ziessel et al.5b (B) Chen et al.6  
! 143 
5.2.1 BODIPY Synthesis from Pyrrole and Aromatic Aldehyde 
 BODIPY derivatives can be synthesized via condensation of an !-free pyrrole and an 
aromatic aldehyde (Scheme 5.1).1 The reaction is catalyzed by TFA or a Lewis acid, in varying 
solvents, depending on the solubility of the reactants. This reaction generally proceeds at room 
temperature and produces a dipyrromethane, an intermediate that is not often isolated before 
pursuing subsequent procedural steps. The dipyrromethane is then oxidized to dipyrromethene 
using DDQ or p-chloranil. Boron trifluoride diethyl etherate (BF3.Et2O) is used to complex the 
pyrrolic nitrogens to boron. This remains a primary method to synthesize a BODIPY, more 
specifically, through the use of aromatic aldehydes, creating a meso-substituted aromatic group 
at position 8 (Scheme 5.1, for example).1, 3, 10 Additionally, in the case of Scheme 5.1, using an 
alternative method, such as the use of an acyl chloride, to synthesize this particular BODIPY 
may have caused chemoselectivity issues, inevitably yielding a 2-ketopyrrole instead of the 
desired phenolic product.1, 10-11 Yields for the synthesis of a symmetric BODIPY vary greatly on 
the substituents on the pyrrole and aldehyde. Our group has produced BODIPYs using this 
method in in 55-90% yields.12 This method can be generalized to most substituted pyrroles and 
aldehydes and usually produces symmetric BODIPY systems with 8-aryl substitution. 
 
Scheme 5.1. Synthesis of BODIPY via Condensation of Pyrrole and Aromatic Aldehyde. 
































R1 = R2 = R3 = R4 = H
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5.2.2 BODIPY Synthesis from Pyrroles and Acylated Compounds (Acetone, Acid 
Chlorides, and Anhydrides) 
 
The first BODIPY synthesized by Treibs and Kreuzer in 1968 involved the condensation 
of 2,4-dimethyl-1H-pyrrole with acetone using BF3.Et2O as the catalyst (Scheme 5.2).3 While 
only 9% yield was obtained of this product, this later propelled the syntheses of other BODIPY 
dyes by this method. It is important to note that this particular reaction Scheme 5.2 involved 
conjugation at positions 3 and 5 of the BODIPY core.  The substituents at these positions varied 
from more electron-donating aromatics (e.g. 4-MeOC6H4, 2-MeOC6H4) to electron-withdrawing 
aromatics (e.g. C6H4, 1-C10H7, 4-FC6H4).13   The unfortunate result of this type of reaction for the 
BODIPY core is that unstable dipyrromethene intermediates (hydrochloride salt derivatives) are 
formed and cannot be isolated.1 The BODIPY core is finalized by complexation of the boron 
difluoride to the pyrrolic nitrogens using base (Et3N or iPr2EtN) and subsequent addition of 
BF3.Et2O in a suitable solvent.1, 13! 
 
A similar method has been considered as one of the most efficient methods in obtaining 
8-substituted BODIPY dyes. In work published by Burgess et al, a condensation of pyrrole and 
an aromatic acid chloride (4-iodobenzoyl chloride) resulted in the aromatic substituent at 



















Scheme 5.2. Synthesis of BODIPY via Condensation of Pyrrole and Acetone. 
(Example by Loudet et al.1a,b) 
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It bears mentioning that non-aromatic acylated substituents can also be incorporated onto 
the BODIPY at the meso-position. Such a method might include using an anhydride, such as 
glutaric anhydride, to end in a carboxylic acid-terminated BODIPY, which can be carried into 
other syntheses, such as the conjugation of peptides, proteins, or peptidomimetics to the 
BODIPY for biological and medicinal applications.1, 14 It has been reported that alkylation (in the 
case of glutaric anhydride) or arylation (in the case of 4-iodobenzoyl chloride) at the meso-
position does not red shift absorption or emission of the BODIPY.1 
5.2.3 BODIPY Synthesis from Ketopyrroles 
In the case of the BODIPY used in this study, another synthesis must be conducted due to 
the unsymmetrical nature of this BODIPY. The aforementioned methods, in sections 5.2.1 and 
5.2.2, will strictly yield symmetrical BODIPY cores. The method used to obtain unsymmetrical 
BODIPYs is through the use of ketopyrroles, although these must be prepared before 
condensation with another pyrrole. This method, however, can produce symmetrical products,1, 5a 
but is most favorable for unsymmetrical BODIPY dyes because the ketopyrrole is usually 
















R = (a) C6H4 (36%), (b)1-C10H7 (90%), (c) 4-MeOC6H4 (99%), (d) 4-FC6H4 (99%), (e) 2-MeOC6H4 (94%)
R R R R
Scheme 5.3. Synthesis of BODIPY via Condensation of Varying !-Substituted Pyrroles and 
Aryl Acid Chloride (4-iodobenzoyl chloride). 
(Example by Loudet et al.1a,b) 
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condensation method, phosphorous oxychloride (POCl3), is often used.1, 5a, 15 Other examples of 
this condensation also use TFA.5a, 15 The final complexation step requires the Lewis acid, 
BF3.Et2O, yielding the BODIPY core of interest. An example of the acidic condensation of a 
ketopyrrole with another varyingly substituted pyrrole is shown in Scheme 5.4. The 
formylpyrrole in the Scheme (5.4) could be synthesized via the method by Treibs and Kreuzer 
(Scheme 5.1).3 Although the synthesis of the BODIPY used in this project is not published, due 
to its existence being proprietary from InvitrogenTM (now, Life TechnologiesTM), it is proposed 
that this BODIPY would undergo synthesis via the ketopyrrole method, due to its varying 
functionalities on each pyrrole. The structure of 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-5-
indacene-3-pentanoic acid succinimidyl ester, or BODIPY ® FL succinimidyl ester (SE), is 
illustrated in Figure 5.3.!!
 
 
Scheme 5.4. Synthesis of BODIPY via Ketopyrroles. 
(Example by Loudet et al.1a,b) 
 

























5.3 HER-2 and its Implication in Breast Cancer 
 Growth factors, more specifically, the human epidermal growth factors, EGFR/HER-
1/ERBB1, HER-2/ERBB2, ERBB3 and ERBB4, are important to consider in the proliferation of 
tumors.  HER-1 and HER-2 have been associated with various cancers through their over-
expression on the cell surfaces of these tumors.16 The four variations of human EGFR are similar 
in structure and activity.  Each receptor exists as a monomer, consisting of an extracellular 
domain (containing four domains (I-IV)), a transmembrane domain (or the “membrane-spanning 
region”), a cytosolic tyrosine-kinase-containing domain, and the regulatory domain, through 
which cell signaling to the nucleus occurs.16a, 16h, i, 17 The process of cell signaling is important to 
the overall activity of a cell, as this activity dictates the type of proteins necessary for accurate 
cellular function.  Additionally, although the growth factors have similar features and objectives, 
there is a staunch difference between HER-2 and the other ERBBs.  The primary difference is in 
the ligand binding; ERBBs 1, 3, and 4, each contain a specific binding ligand, a molecule which 
attaches to the receptor prior to dimerization.16e, f  For example, for HER-1/ERBB1, the binding 
ligand is epidermal growth factor (EGF), a polypeptide consisting of fifty-three amino acids.16c 
Once EGF binds to the active site on the inactive, or tethered confirmation of HER-1/ERBB1, 
the confirmation is then “activated” and may subsequently pair, or dimerize, with another growth 
factor.16a, 16e, f There are other ligands which bind to HER-1, such as transforming growth factor-
! (TGF-!) or amphiregulin (AR).16a, 18 However, for ERBB3 and ERBB4, other ligands bind 
preferentially, most notably the neuregulins (NRGs).16a, 19 HER-2 has been implicated as the only 
growth factor that permanently exists in an “activated” confirmation and does not require any 
ligand binding to achieve activity. HER-2 has been identified as the growth factor receptor that 
binds to each of the other ERBBs at a very high rate.16a, 20 While ERBB1, ERBB3, and ERBB4 
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may each homodimerize, or the process of two of the same ERBBs combining in the 
extracellular domain, it is prominently found that HER-2 consistently binds preferentially to each 
of these receptors through heterodimerization.16a  Also, HER-2 can bind to itself repeatedly, thus 
initiating the over-expression of this receptor due to high concentrations of HER-2 at the plasma 
membrane.16a To illustrate these concepts, two Figures (5.4 and 5.5) propose structures and 
binding mechanisms for the ERBBs.  Figure 5.4 highlights a general structure of the non-ligand 
binding, activated HER-2 exhibiting each of its domains. Figure 5.5 illustrates the dimerization 
of activated HER-2 with another tethered ERBB monomer, such as EGFR (HER-1) or ERBB3. 
In this Figure (5.5), it is shown that a ligand must bind to the previously inactivated monomer 
before heterodimerization with HER-2.  The generalized ligand binds to domains I and III of the 
ERBB extracellular domain.  Examples of this include EGF and the NRGs.16a 
This project’s focus is to develop molecules, more specifically, peptidomimetics, that 
preferentially attach to HER-2, which has been studied over the past decade as a target for the 
treatment of breast cancer.16h, i While HER-2 positive breast cancer is one tumor subtype,21 there 
are breast tumors that are basal-like,21a, b, 22 luminal-like (most common form),21a, b, 23 and normal 
breast tissue-like.21a, b, 24 HER-2 over-expressed breast cancers, however, are very aggressive. 
These types of breast cancers over-express HER-2 by over 30% and, unfortunately, have a very 
unfavorable prognosis - varying between 60-72 months, unless found at a very early stage.20-21 If 
efforts are placed toward developing highly specific molecules for HER-2, this could improve 
the current treatment options. Currently, individuals who have been diagnosed with HER-2 
positive breast cancer are treated with high molecular weight, uncharacterized antibodies 
(mAbs), for example, Tratstuzumab (Herceptin; manufactured by Genentech/Roche) or 
Pertuzumab (Omnitarg; nanufactured by Genentech).21b Trastuzumab binds to domain IV of 
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ERBB2, while Pertuzumab binds to domain II of ERBB2. Neither of these mAbs are highly 
effective in treating HER-2 positive breast cancers because of the ability of the cancer cells to 
further mutate, thus gain increased resistance to these agents.  In fact, the efficacy of these mAbs 
has been thoroughly studied through clinical trials; Trastuzumab only assists in treating one-third 
of HER-2 over-expressed breast cancer, while Pertuzumab only treats breast cancers which are 
HER-2 positive, but contain low levels of the receptor.16a These facts also accentuate that each 
mAb binds to different domains of HER-2; binding of Trastuzumab to domain IV is a completely 
uninvolved region in the homo- or hetero-dimerization of ERBBs, while the binding of 
Pertuzumab to domain II is the essential region for either dimerization form (as illustrated in 
Figure 5.5).16a, 20  In any case, these mABs are not extremely effective for treatment.  Therefore, 
developing smaller, highly specific, fully characterizable molecules, such as peptidomimetics, 
may increase survival time of individuals with HER-2 positive breast cancers, whether this 
receptor is over-expressed or not.  Although smaller molecules, such as the tyrphostins 
mentioned in Chapter 3, that bind to the ATP site of the ERBB tyrosine kinase domain, have 
been approved for clinical use in the treatment of cancers that over-express other ERBBs, there 
has not been a molecule of low molecular weight approved for the treatment of HER-2 breast 
cancers.  
5.4. Development and Biological Studies of HERP5 Peptidomimetic 
 This work focuses on conjugation of fluorescent BODIPY (Figure 5.3) to a 
peptidomimetic - a low molecular weight peptide that simulates the functionality and structure of 
a larger peptide or protein - illustrated to have an affinity for HER-2 through recent in vitro 
studies by Satyanarayanajois and colleagues.16h This three amino acid peptidomimetic was 
developed through computational experimentation and subsequently tested in cell culture to  
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Figure 5.5. Heterodimerization of HER-2 with Another ERBB Monomer. 
Figure 5.4. HER-2 Generalized Structure With Essential Regions. 
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determine its inhibitory effect when bound to HER-2. Figure 5.6 shows the structure of the 
peptidomimetic, termed HERP5.16h, i Although other peptidomimetics were developed, the 
combination of computational work and biological study on this derivative of HERP5 verifies 
the great potential for this molecule. 
5.4.1 Computational Development of HERP5 
 The use of computational chemistry in drug development has become of utmost 
importance in recent years. Programming of new computational software has opened the arena of 
biological docking to organic chemists and biologists alike. Using docking programs, such as 
AutoDOCK,25 allows for synthetic methods to be realized, and in many cases, proves to be a 
very effective method for finding active sites, low energy conformations, and geometrically 
stable molecules, which all bind to a molecule of choice in consideration of an implicit or 
explicit environment.25-26  This is the case for the development of the HERP5 peptidomimetic 
(Figure 5.6). 
    
EGFR and other members of the ERBB family have been well characterized by crystal 
structure.  This is evidenced by the vast information available about EGFR on the Protein Data 
Bank website.27  Additionally, there are many ligands known to bind to ERBBs 1, 3, and 4, 
















preferentially.16a  For determination of peptidomimetic HERP5, the crystal structure of HER-2 in 
complex with Trastuzumab (Herceptin) was used (PDB ID: 1N8Z).16h, i, 18 There are three regions 
deemed important for binding Herceptin to HER-2: two regions contain integral electrostatic 
interactions with the mAb, while another region serves as a hydrophobic binding region for 
Herceptin.16h, 18 The electrostatic regions of the binding site between HER-2 and Herceptin 
consist of acidic and basic residues, such as arginine (R) and lysine (K), whereas the 
hydrophobic space of the site is occupied by phenylalanine (F) and proline (P). The hydrophobic 
region is bordered on each side by the electrostatic regions. Therefore, the peptidomimetics were 
designed using a generalized structure order: an N-terminal arginine, followed by a 
conformationally constrained hydrophobic "-amino acid (such as 1-naphthyl alanine), and C-
terminated with phenylalanine. Using a hydrophobic "-amino acid like 1-naphthyl alanine 
minimizes proteolytic degradation of the peptide and reduces the amount of flexibility of the 
peptide in biological conditions (aqueous), therefore restricting the possible conformation of the 
molecule (i.e. random coil, "-sheet, or !-helix).16h, 18 A "-sheet confirmation of the HERP5 
peptide was confirmed in recent work.16i On the other hand, supplementary computational 
(docking) showed favorable results. Two software programs, AutoDOCK25 and INSIGHT II,28 
were used to determine the chemical space for the molecule and also achieve the most 
energetically favorable conformations of the HERP5 peptidomimetic.  In this work, five 
derivatives of HERP5 were reported with low energies between -13.87 to -13.31 kcal/mol.16h 
5.4.2 Antiproliferative Activity of HERP5 
The antiproliferative activity of HERP5 was studied in three different cell lines: HCT 116 
(human colon cancer cells), MCF-7 (human breast cancer cells), and SKBR-3 (human breast 
cancer cell line with epithelial morphology).  The IC50 micromolar concentrations for HERP5 in 
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these three cell lines were 25.7 (HCT 116), 16.9 (MCF-7), and 0.396 (SKBR-3), giving the 
lowest inhibitory concentrations compared to six other peptide derivatives that were studied.  
This data confirms that this molecule should be further investigated by conjugation to a 
fluorescent marker as potential treatment for HER-2 positive breast cancers. 
5.5 Synthesis of BODIPY-HERP5 Conjugates 
 The synthesis of the BODIPY-HERP5 conjugates was accomplished using three 
methods: 1. Synthesis of a C-terminal tert-butyl ester protected HERP5 peptide and subsequent 
solution phase conjugation to BODIPY, 2. Synthesis of HERP5 conjugate via solid phase peptide 
synthesis (SPPS) on the Rink Amide resin (C-terminal amide functionality), and 3.  Synthesis of 
HERP5 conjugate via SPPS on the Wang resin (C-terminal carboxylic acid functionality). 
5.5.1 Synthesis of BODIPY-HERP5 tert-Butyl Ester Terminated Conjugate 
The first synthesis of unprotected 5-1 was customized by NeoMPS (San Diego, CA, 
USA) and a later purchase of the free peptide was made from New England Peptide (Gardner, 
MA, USA).  It was first attempted that 5-1 be directly conjugated to the commercially available 
5-3, under basic conditions (Et3N) to allow for direct and, apparently unproblematic, conjugation 
to 5-3.  However, after several studies, it was verified by NMR that 5-1 tends to dimerize and 
polymerize when using these conditions, thus suggesting that one end of 5-1, N- or C-terminal, 
must contain a protecting group before conjugation with the fluorophore. This method, then, 
protects the C-terminus of 5-1 with a tert-butyl ester, which is stable under the basic conditions 
needed for conjugation.  The tert-butyl ester can be formed by several methods, including strong 
acidic conditions.  Mechanistically, the reaction is acid catalyzed with sulfuric acid, then tertiary 
butanol is added to complete the esterification.  To prevent water from forming, causing 
hydrolysis of the ester, anhydrous magnesium sulfate was added.29 The primary issue with this 
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method is that the yields were moderate (54%) and did not give enough product for further 
significant study.  Several trials were conducted with the aim to optimize the with consistently 
moderate yields obtained.  To proceed with the conjugation, after aqueous work-up in sodium 
bicarbonate, the product was immediately subjected to solution phase conjugation to 5-3 in DMF 
for 72h, as shown in Scheme 5.5.  The yield for this synthesis was 20%, giving less than 0.001 g 
of product, 5-4. If this method continued, the C-terminal ester would have been deprotected with 



















































1. Et3N, DMF, 4h










Scheme 5.5. Synthesis of BODIPY-HERP5 tert-Butyl Ester Terminated Conjugate. 
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5.5.2 Synthesis of BODIPY-HERP5 Rink Amide Conjugate 
After achieving moderate yields of 5-4, it was proposed that the synthesis of these 
conjugates can be performed via SPPS.  Therefore, the peptide, 5-1, was synthesized on two 
different resins, one being the Rink Amide resin (Figure 5.7), and the other, the Wang Resin 
(Figure 5.8).  This resin was selected for several reasons.  First, this resin provides the final 
cleaved peptide with a C-terminal amide functionality, which gives a stable C-terminus and 
avoids protection of the C-terminal carboxylic acid, as was conducted to afford product 5-2. The 
peptide, synthesized via benchtop SPPS by our group, yielded the C-terminal amide HERP5 (5-
6) anchored to the Rink Amide resin. The Fmoc-group remained on the N-terminal arginine to 
preserve the structure and function of the peptide between syntheses, as illustrated in compound 
5-6 and the Fmoc-group was cleaved using piperidine and DBU (in DMF) prior to coupling, 
giving compound 5-7.  Conjugation of 5-3, as shown in Scheme 5.7, to this resin involved 
reaction of the succinimidyl ester in Et3N and DMF for one hour before adding this !solution to a 
peptide synthesis chamber containing the swelled 5-7 peptide.  The conjugation, again, 
proceeded for a total of 72 h. The progress of the reaction was monitored by selecting a few resin 
beads from the chamber, subjecting them to the “cleavage cocktail” consisting of TFA (88%), 
liquefied phenol (5%), triisopropylsilane (2%), and water (5%) for 4 h, then submitting this small 
sample for mass spectrometry analysis.  Once the mass of the conjugate was confirmed, the 
entire conjugate was cleaved from the resin using the aforementioned cleavage cocktail, dried, 
and washed with cold ether to remove scavengers.  Because of the more hydrophobic nature of 
this conjugate, it was purified by preparative TLC (10% MeOH/90% DCM) and yielded 60% of 
conjugate 5-8.  This process of synthesis improved the conjugation yield significantly.  
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5.5.3 Synthesis of BODIPY-HERP5 Wang Conjugate 
As stated previously in Section 5.4 of this Chapter, the computational studies and 
antiproliferative activity was conducted using the C-terminal carboxylic acid HERP5 (5-1). 
Therefore, the peptide 5-1, had to be synthesized on another type of resin, the Wang resin 
(Figure 5.8). This resin provides the final cleaved peptide with a C-terminal carboxylic acid 
functionality. This peptide was also synthesized via benchtop SPPS by our group and yielded the 
Fmoc-protected C-terminal HERP5 (5-9) anchored to the Wang resin. The Fmoc-group remained 
on the N-terminal arginine, once again, to preserve the structure and function of the peptide 
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Scheme 5.6. Synthesis of BODIPY-HERP5 Rink Amide Conjugate. 
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Scheme 5.8, to this resin involved reaction of the succinimidyl ester in Et3N and DMF for one 
hour before adding this solution to a peptide synthesis chamber containing the swelled 5-10 
peptide.  The conjugation proceeded for a total of 72 h. Selecting a few resin beads from the 
chamber, subjecting them to the “cleavage cocktail” for 4 h, then submitting this small sample 
for mass spectrometry analysis, was used again to monitor the progress of the reaction.  Once the 
mass of the conjugate was confirmed, the entire conjugate was cleaved from the resin (using the 
aforementioned cleavage cocktail), dried, and washed with cold ether to remove scavengers.  
Because of the more hydrophobic nature of this conjugate, it was purified by preparative TLC 
(10% MeOH/90% DCM) and yielded 45% of conjugate 5-11.  Although the yield was not as 
high as the resulting 5-8 conjugate, the conjugation yield was better than the original process 
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Figure 5.8. Structure of Wang Resin. 
Scheme 5.8. Synthesis of BODIPY-HERP5 Wang Conjugate. 
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!5.6 Conclusion 
 This chapter aimed to illustrate the different synthetic methodologies to obtain BODIPYs 
as well as give an overview of the synthetic methods to obtain two BODIPY-peptidomimetic 
conjugates.  The most effective method for conjugating BODIPY 5-3 was via SPPS. Future 
cellular studies will illustrate the efficacy of these BODIPY-peptidomimetic conjugates to image 
and/or potentially treat cancers that have an over-expression of HER-2. 
 
5.7 Experimental  
Synthesis of tert-butyl Arg-[3-amino-3-(1-napthyl)-propionic acid]-Phe (5-2): In a small 
round bottom flask, anhydrous magnesium sulfate (0.232 mg, 0.001928 mmol) in 3 mL of dry 
DCM was stirred vigorously for 10 minutes. Excess concentrated sulfuric acid (92.00 mg, 0.9380 
mmol) was added to the flask. The mixture was stirred for 1 h. 5-1 (0.25 mg, 4.8206E-4 mmol) 
was then added to the mixture. The flask was sonicated to ensure solubility and stirred for an 
additional 5 minutes before adding tertiary butanol (0.228 uL, 0.002410 mmol).  The flask was 
stoppered and stirred for 24 h at 25oC under N2 gas.  The reaction was quenched with saturated 
sodium bicarbonate (3 mL) by adding this to the reaction flask until all of the magnesium sulfate 
had dissolved.  The organic phase was separated, washed with brine, dried with Na2SO4, and 
purified by preparative TLC to afford the t-butyl protected HERP5 (5-2) in 54% yield (0.15 mg). 
1H NMR (400 MHz, Acetone) d ppm 0.82 - 0.91 (m, 6 H) 1.28 (br. s., 9 H) 1.51 - 1.62 (m, 1 H) 
2.94 (br. s., 4 H) 3.25 - 3.32 (m, 1 H) 4.57 - 4.63 (m, 1 H) 5.34 (t, J=4.57 Hz, 1 H) 6.24 - 6.31 
(m, 1 H) 7.21 (s, 1 H) 7.31 (d, J=4.26 Hz, 1 H) 7.42 - 7.47 (m, 1 H) 7.50 - 7.64 (m, 3 H) 7.77 - 
7.89 (m, 1 H) 7.93 (d, J=7.31 Hz, 1 H) 8.02 (s, 2 H) 8.15 - 8.24 (m, 1 H). MALDI-TOF: 
C32H44N604 [M]+: 577.351, calcd. for C32H45N604: 577.71.  
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Synthesis of BODIPY succinimidyl ester tert-butyl Arg-[3-amino-3-(1-napthyl)-propionic 
acid]-Phe (5-4): To a small round bottom flask was added 5-3 (0.826 mg, 0.001979 mmol) in 
peptide synthesis grade DMF (1 mL). Compound 3 was sonicated to ensure solubility.  Six (6) 
equivalents of triethylamine (1.65 uL, 0.001979 mmol) were added to the flask. Compound 5-3 
was activated for 4.5 h under inert conditions (N2 gas) before compound 5-2 (2.3 mg, 0.001979 
mmol) in 0.5 mL peptide synthesis grade DMF was added to the flask.  Conjugation took place 
for 72 h under nitrogen. Confirmation of mass was observed by ESI-MS. HRMS (ESI) [M-tBu]: 
820.73, calcd. for C48H59BF2N8O5: 876.84; MALDI-TOF (Figure 5.10) C48H61BF2N8O52+ 










































Fmoc Deprotection of Arg-[3-amino-3-(1-napthyl)-propionic acid]-Phe on Rink Amide 
Resin (5-7): Resin 5-6 (0.0025 g, 0.004794 mmol) was swelled in peptide synthesis grade DMF 
for 1 h. A fresh “deblock solution” (25.00 mL) was prepared consisting of piperidine (1.25 mL), 
DBU (0.50 mL), and DMF (23.25 mL). The deblock solution was added to the chamber such that 
it completely covered the resin beads over three timed settings: 1 x 8 min, 1 x 5 min, 1 x 7 min. 
The final step requires washing with DMF (5 times with vigorous stirring) and vacuum drying.  
The peptide was used immediately in the following step. ESI-MS. 740.338 [M+H]+, Calculated 
for C43H45N7O5  739.86. 
 
 
Figure 5.12. Compound 5-7 MALDI-TOF. 
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Conjugation of 5-3 to Arg-[3-amino-3-(1-napthyl)-propionic acid]-Phe on Rink Amide 
Resin (5-8): To a reaction vessel was added compound 5-3 (0.0015 g, 0.002397 mmol) and 
solubilized in 0.5 mL DMF. Triethylamine (0.002 mL, 0.002397 mmol) was added to the vessel 
and stirred to activate the ester.  The reaction continued for 1 hr. This solution was added to the 
peptide synthesis chamber containing 5-7 (0.0025g, 0.004794 mmol). The reaction proceeded 
with shaking for approximately 72 h under N2.  The beads were then washed with DMF 4 times, 
to remove residual 5-3, until the filtrate was colorless.  A “cleavage cocktail” consisting of 1 mL 
of TFA (88%), liquefied phenol (5%), triisopropylsilane (2%), and water (5%) was added to the 
resin beads for 4 h.  The resin was filtered and washed with TFA (3 x 1 mL).  Filtrates were 
combined, evaporated, and washed with cold anhydrous ether.  Purification was conducted by 
preparative TLC (10% MeOH/90% DCM) to yield 51% of conjugate. 1H NMR (400 MHz, 
DMF) d ppm 0.13 (br. s.,  <1 H) 0.87 (br. s., 4 H) 1.43 (br. s., 1 H) 1.51 - 1.60 (m, 4 H) 1.64 (br. 
s., 3 H) 2.04 (d, J=2.44 Hz, 3 H), 2.14 (br. s., 3 H) 3.11 (br. s., 2 H) 3.16 (br. s., 1 H) 3.21 (br. s., 
Figure 5.13. MALDI-TOF of Compound 5-8.!
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1 H) 3.28 (br. s., 2 H) 3.39 (br. s., 2 H) 3.92 - 3.99 (m, 2 H) 5.36 (br. s., 1 H) 5.43 (br. s., 1 H) 
6.65 (s, 1 H) 7.19 (br. s., 2 H) 7.24 (br. s., 2 H) 7.30 (br. s., 1 H) 7.32 (br. s., 1 H) 7.42 (br. s., 1 
H) 7.49 - 7.73 (m, 3 H) 8.40 (d, J=4.87 Hz, 2 H) 8.51 (br. s., 1 H). MALDI-TOF [(M+H)-BF2]: 
C44H54N9O4 772.59, calcd. for C44H54N9O4 771.95. # (nm) ($, L mol!1 cm!1): 565 nm 
(1.84E+05), 463 nm (4.85E+05).  
 
 
 Figure 5.14. 
1H NMR of Conjugate 5-8. 
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Figure 5.13 and Table 5.1: MALDI-TOF-TOF Fragmentation of Conjugate 5-8.!
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Fmoc Deprotection of Arg-[3-amino-3-(1-napthyl)-propionic acid]-Phe on Wang Resin (5-
10): Resin 5-9 (0.0050 g, 0.004794 mmol) was swelled in peptide synthesis grade DMF for 1 h. 
A fresh “deblock solution” (25.00 mL) was prepared consisting of piperidine (1.25 mL), DBU 
(0.50 mL), and DMF (23.25 mL). The deblock solution was added to the chamber such that it 
completely covered the resin beads over three timed settings: 1 x 8 min, 1 x 5 min, 1 x 7 min. 
The final step requires washing with DMF (5 times with vigorous stirring) and vacuum drying.  
The peptide was used immediately in the following step. MALDI-TOF 741.551 [M+H]+, 





Figure 5.16.  Compound 5-10 MALDI-TOF. 
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Conjugation of 5-3 to Arg-[3-amino-3-(1-napthyl)-propionic acid]-Phe on Wang Resin (5-
11): To a reaction vessel was added compound 5-3 (0.0021 g, 0.002397 mmol) and solubilized in 
0.9 mL DMF. Triethylamine (0.006 mL, 0.002397 mmol) was added to the vessel and stirred to 
activate the ester.  The reaction continued for 1 hr. This solution was added to the peptide 
synthesis chamber containing 5-10 (0.0050 g, 0.004794 mmol). The reaction proceeded with 
shaking for approximately 72 h under N2.  The beads were then washed with DMF 4 times, to 
remove residual 5-3, until the filtrate was colorless.  A “cleavage cocktail” consisting of 1 mL of 
TFA (88%), liquefied phenol (5%), triisopropylsilane (2%), and water (5%) was added to the 
resin beads for 4 h.  The resin was filtered and washed with TFA (3 x 1 mL).  Filtrates were 
combined, evaporated, and washed with cold anhydrous ether.  Purification was conducted by 
preparative TLC (10% MeOH/90% DCM) and analytical HPLC (ACN/H2O) to yield 45%-65% 
of conjugate. 1H NMR (400 MHz, DMF) d ppm 2.00 (br. s., 3 H) 2.42 (d, J=10.96 Hz, 2 H) 2.47 
(br. s., 1 H) 2.54 (d, J=4.87 Hz, 2 H) 2.58 (s, 1 H) 2.76 (br. s., 2H) 3.20 (br. s., 2 H) 3.24 (br. s., 1 
H) 3.37 (br. s., 3 H) 3.96 (br. s., 4 H) 4.14 (d, J=15.23 Hz, 2 H) 4.24 (br. s., 1 H) 4.63 (s, 2 H) 
4.75 (br. s., 1 H), 4.80 (br. s., 2 H) 4.92 (br. s., 1 H) 6.26 - 6.39 (m, 2 H) 7.26 (s, 1 H) 7.35 (br. s., 
2 H) 7.69 - 7.78 (m, 4 H) 7.99 (s, 1 H) 7.95 (s, 1 H) 8.12 (s, 1 H), 8.47 (br. s., 1 H) 9.03 (s, 1 H). 
MALDI-TOF [M+H]: C44H52BF2N8O5 821.41, calcd. for C44H51BF2N8O5 820.73. # (nm) ($, L 







Figure 5.17. HRMS ESI of Conjugate 5-11. 
Figure 5.18. 1H NMR of Conjugate 5-11.!
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Figure 5.19 and Table 5.2: MALDI-TOF-TOF Fragmentation of Conjugate 5-11.!
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